

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 541 167 A1

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

AM

(43) Date of publication:  
15.06.2005 Bulletin 2005/24

(51) Int Cl.7: **A61K 38/17**, A61P 37/08,  
A61K 7/00, A61K 7/48,  
A61K 35/64

(21) Application number: 03791308.4

(22) Date of filing: 26.08.2003

(86) International application number:  
PCT/JP2003/010795

(87) International publication number:  
WO 2004/019971 (11.03.2004 Gazette 2004/11)

(84) Designated Contracting States:  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 29.08.2002 JP 2002252087  
30.01.2003 JP 2003022776

(71) Applicant: Hayashibara, Ken  
Okayama-shi Okayama700-0921 (JP)

(72) Inventors:  
• OKAMOTO, Iwao, c/o K. K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)

• ARAI, Norie, c/o K. K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)  
• KOHNO, Kelzo, c/o K. K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)  
• KURIMOTO, Masashi, c/o K. K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)  
• SANO, Osamu, c/o K. K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)


(74) Representative: Daniels, Jeffrey Nicholas et al  
Page White & Farrer  
54 Doughty Street  
London WC1N 2LS (GB)

**(54) ANTIALLERGIC AGENT**

(57) It is intended to provide an anti-allergic agent,  
which efficaciously relieves symptoms accompanying  
an allergic disease without causing any serious side ef-

fect. This object is achieved by providing an anti-allergic  
agent which contains, as an effective ingredient, pro-  
teins collected from royal jelly or purified royal jelly, or  
royal jelly or purified royal jelly containing the proteins.

FIG.4



EP 1 541 167 A1

**Description****TECHNICAL FIELD**

**[0001]** The present invention relates to an anti-allergic agent, more particularly, to an anti-allergic agent comprising, as effective ingredients, proteins obtainable from intact royal jelly or purified royal jelly, and to an anti-allergic agent comprising intact royal jelly or purified royal jelly which contains the proteins.

**BACKGROUND ART**

**[0002]** In these days, change in diet, etc. has brought a problem of increasing patients suffering from allergic diseases. Particularly, the increase of atopic diseases such as pollinosis, atopic dermatitis, bronchial asthma, allergic rhinitis and contact hypersensitivity has become to be a serious problem. Anti-histamic agents or steroids have been usually administered to symptomatically treat allergic diseases. However, such agents have a problem of causing serious side effects in their long-term use. Under these circumstances, a method for treating allergic diseases, which enables to effectively alleviate various symptoms thereof and which is applicable for a long-term use without affecting daily life, has been desired.

**[0003]** Recently, royal jelly (may be abbreviated as "RJ", hereinafter) has been arousing public interest as a health food, while its various biological activities have been confirmed. Royal jelly is known to be a milky secretion from the exocrine of worker bees, and it is stored in queen cells in beehives, and it is a food for a larva to become a queen bee. Varying depending on its origin and harvesting season, the composition of royal jelly is known to be slightly changed in the range of 65-75% of water, 15-20% of proteins, 10-15% of carbohydrates, 1.7-6% of fats, and 0.7-2% of ash. J. Schimitszova *et al.* has succeeded to clone cDNAs of five major proteins contained in royal jelly using honeybee (*Apis mellifera*) and revealed their nucleotide sequences and putative amino acid sequences. The five proteins were named as "MRJP1", "MRJP2", "MRJP3", "MRJP4", and "MRJP5" by abbreviating the following capitals of "major royal jelly protein". However, these proteins have not yet been studied on their biological activities.

**[0004]** Under the above circumstances, the present invention has an object to provide a method for effectively alleviating various symptoms caused by allergic diseases without causing serious side effects when applied to patients in need thereof.

**DISCLOSURE OF THE INVENTION**

**[0005]** The present inventors have eagerly studied on royal jelly to attain the above object. As a result, they revealed that a kind of low-molecular or high-molecular component, concretely, a protein having a partial amino acid sequence of SEQ ID NO: 1 or 2, remarkably inhibits the production of antibodies and/or cytokines in living bodies, and confirmed that it effectively alleviates various symptoms caused by allergic diseases without serious side effects.

**[0006]** The present invention solves the above object by providing an anti-allergic agent comprising the proteins obtained from intact royal jelly or a purified royal jelly, and anti-allergic agent comprising intact royal jelly or purified royal jelly which contains the proteins.

**[0007]** Also, the present invention solves the above object by providing foods and beverages comprising the above anti-allergic agent.

**[0008]** Further, the present invention solves the above problem by providing cosmetics comprising the above anti-allergic agent.

**[0009]** Furthermore, the present invention solves the above problem by providing pharmaceuticals comprising the above anti-allergic agent.

**BRIEF DESCRIPTION OF DRAWINGS****[0010]**

FIG. 1 shows a two-dimensional electrophoresis pattern of anti-allergic proteins of the present invention contained in a raw royal jelly.

FIG. 2 is a chromatogram showing elution pattern of an active protein by applying a water-soluble protein fraction of royal jelly to an anion-exchange column chromatography using DEAE-5PW gel. (Open circles mean a relative production of IL-2; closed circles mean a relative production of IL-4; open triangles mean a relative cell proliferation rate, "No.1" means an elute fraction of "Active Protein No.1"; "No.2" means an elute fraction of "Active Protein No.2".)

FIG. 3 is a chromatogram showing an elution pattern of an active protein by applying "Active Protein No.1" to an

affinity chromatography using Heparin-5PW gel. (Open circles mean relative production of IL-2; closed circles mean relative production of IL-4; open triangles mean relative cell proliferation rate, "No.1" means elute fraction of "Active Protein No.1-1"; "No.2" means elute fraction of "Active Protein No.1-2".)

FIG 4 shows a result of measuring anti-OVA IgE antibody value in serum of OVA/Alum immunized male BALB/c mouse when intraperitoneally administered with royal jelly or "RJP70". (Closed circles mean data of five each mouse, "-" means average, "\*" means data having significantly different data by 5% or less of relative risk.)

FIG 5 shows a result of measuring anti-OVA IgG1 antibody value in serum of OVA/Alum immunized male BALB/c mouse when intraperitoneally administered with royal jelly or "RJP70". (Closed circles mean data of five each mouse, "-" means average, "\*" means data having significantly different data by 5% or less of relative risk.)

#### BEST MODE FOR CARRYING OUT THE INVENTION

**[0011]** The present invention relates to an anti-allergic agent comprising, as effective ingredients, proteins obtainable from intact royal jelly or purified royal jelly or to an anti-allergic agent comprising intact royal jelly or purified royal jelly containing the proteins. Royal jelly usable in the present invention is of that secreted from honeybees such as *Apis mellifera*, *Apis cerana*, *Apis dorsata* and *Apis florea*, and it is produced in Japan, South America, North America, Australia, China or Europe. Any royal jelly different in form, purity or preparation can be arbitrarily used as long as it comprises a low-molecular or high-molecular component having an anti-allergic effect. Particularly, such a component is a protein having a partial amino acid sequence of SEQ ID NO: 1 or 2 has an effect on treatment or prevention of allergic diseases such as atopic allergy, tissue specific allergy, immune complex allergy and delayed type allergy when applied to mammals including humans selectively after through appropriate purification.

**[0012]** Royal jelly can be purified by applying usual purification methods for other low-molecular or high-molecular biologically active substances when it has not enough anti-allergic activity. The term "purified royal jelly" as referred to as in the present invention means those having a higher content of an objective ingredient on a dry solid basis purified by partially removing some of unnecessary ingredients from a raw royal jelly. As such a water-soluble protein fraction of a royal jelly is preferably used in the present invention. Examples of such purification method is illustrated with filtration, concentration, dry, centrifugation, sedimentation, salting out, dialysis, ion-exchange chromatography, gel filtration chromatography, adsorption chromatography, isoelectric chromatography, hydrophobic chromatography, reverse-phase chromatography, affinity chromatography, gel electrophoresis and isoelectric electrophoresis, and optionally, applied with an appropriate combination thereof.

**[0013]** The anti-allergic components contained in royal jelly used in the present invention can be illustrated with proteins having a partial amino acid sequence of SEQ ID NO: 1 or 2. Any protein can be used in the present invention as long as it has partial amino acid sequence represented by SEQ ID NO: 1 or 2 and give an anti-allergic effect on living bodies regardless of its purity, origin and preparation. A preferable protein having biological effect on inhibiting the production of antibodies and/or cytokines is one comprising a partial amino acid sequence represented by SEQ ID NO: 1 or 2 and having a molecular weight of 55,000-70,000 Daltons on SDS-polyacrylamide gel electrophoresis (SDS-PAGE). More preferable one is a protein comprising an amino acid sequence of SEQ ID NO: 3 or 4. Such proteins comprising the above amino acid sequences are extremely useful in the present invention because they remarkably inhibit the production of antibodies and cytokines in living bodies and alleviate various symptoms caused by allergic diseases effectively without causing serious side effects in a relatively long-term administration. The proteins used in the present invention are not restricted to the above-identified proteins. For example, one or more amino acid residues of proteins having the whole amino acid sequence of SEQ ID NO: 3 or 4 can be deleted or replaced with other amino acid residues or one or more amino acids can be inserted in or added to the amino acid sequence of SEQ ID NO: 3 or 4 in such a manner of not substantially eliminating the anti-allergic effect.

**[0014]** The anti-allergic protein having a partial amino acid sequence of SEQ ID NO: 1 or 2 used in the present invention is originated from royal jelly and can be usually obtained from natural royal jelly. The anti-allergic protein can be used after purifying royal jelly as a raw material in a desired level by one or more purification methods. The term "isolated or partially-purified protein having a partial amino acid sequence of SEQ ID NO: 1 or 2" means a protein purified and isolated perfectly or purified partially using purification methods. Such proteins can be advantageously used in the present invention.

**[0015]** The protein having a partial amino acid sequence of SEQ ID NO: 1 or 2 is identified or quantified by measuring its molecular weight using electrophoresis. Examples of electrophoresis are usually illustrated with SDS-PAGE in the presence of a reducing agent, electrofocusing, and two-dimensional electrophoresis in combination thereof. FIG. 1 shows the result of detection for an anti-allergic protein by two-dimensional electrophoresis. The proteins having a partial amino acid sequence of SEQ ID NO: 1 contained in royal jelly have a molecular weight of about 70 kilo-Daltons (kDa) as a major protein and a molecular weight of about 55 kDa as a minor protein on SDS-PAGE in the presence of a reducing agent. The proteins having a partial amino acid sequence of SEQ ID NO: 2 contained in royal jelly have a molecular weight of about 55 kDa on SDS-PAGE in the presence of reducing agent. Hereinafter, in the present spec-

ification, the proteins having the amino acid sequence of SEQ ID NO: 3 of proteins having a partial amino acid sequence of SEQ ID NO: 1 corresponds to the protein called "Active Protein No.1-2" or "RJP70", and the protein having the amino acid sequence of SEQ ID NO: 4 of the proteins having a partial amino acid sequence of SEQ ID NO: 2 corresponds to the protein called "Active Protein No.2" or "RJP55".

**[0016]** As described above, "RJP70" and "RJP55" used as anti-allergic proteins in the present invention have the amino acid sequence of SEQ ID NOs: 3 and 4, respectively. Comparing the amino acid sequences of these proteins with major royal jelly proteins "MRJP 1", "MRJP2", "MRJP3", "MRJP4" and "MRJP5" disclosed by J. Schimitszova *et al.* in "*Cellular and Molecular Life Sciences*", Vol. 54, pp. 1,020 - 1,030, (1998); "RJP70" and "RJP55" were completely identical with "MRJP3" and "MRJP1" at least in their N-terminal regions. Further, J. Schimitszova *et al.* have reported some variants of "MRJP3" showing a molecular weight of 60, 63, 66 or 70 kDa. The protein having a partial amino acid sequence of SEQ ID NO.1 used in the present invention showed both molecular weights of about 70 kDa ("RJP70") and about 55 kDa. While, "RJP55" has the same N-terminal amino acid sequence and molecular weight (55 kDa) as of "MRJP1". They reported that "MRJP1" and "MRJP3" dominated about 31% and 26% of the total amount of royal jelly proteins, respectively. Therefore, "RJP70" and "RJP55" are possibly substantially the same proteins as "MRJP3" and "MRJP1", respectively. However, these proteins have not been studied about their biological activity such as anti-allergic activity at all.

**[0017]** Recombinant DNA technology using a DNA encoding the amino acid sequence of SEQ ID NO: 3 or 4 is applicable for preparing the anti-allergic protein as well as a method of extracting from natural royal jelly. Honeybees are used as an advantageous material for a source of DNA such as mRNA and genomic DNA. The DNA encoding anti-allergic protein "RJP70" or "RJP55" is illustrated with the cloned DNA having the nucleotide sequence of SEQ ID NO: 5 or 6. While, the nucleotide sequences and amino acid sequences of "MRJP3" and "MRJP1", which have been a quite high similarity to "RJP70" and "RJP55", respectively, can be referred to "GenBank" gene database as Accession Nos. Z26318 (SEQ ID NO: 7) and AF000633 (SEQ ID NO:8).

**[0018]** The following evidences were revealed by comparing the nucleotide sequences of the DNA encoding "RJP70" or "RJP55" cloned from *Apis mellifera* with that of "MRJP3" (SEQ ID NO: 7) or "MRJP1" (SEQ ID NO:8). There are five different nucleotides and three different putative amino acid residues due to different nucleotides between "RJP70" and "MRJP3". While, the nucleotide sequence of the DNA encoding "RJP55" completely corresponds to that of "MRJP1", although the 1134th base of the nucleotide sequence of "MRJP1" was described unknown, but it would correspond to thymidine "t" in "RJP55". These differences are summarized in Table 1.

Table 1

	Number of Position	Protein	
		RJP70	MRJP3
Positions of Different Nucleotides *	770	G	A
	819	C	T
	820	T	C
	821	C	T
	861	G	C
Positions of Different Amino Acid Residues **	237	Cys	Tyr
	254	Ser	Leu
	267	Arg	Ser

\*: The numbering starts from "A" of the starting codon "ATG".

\*\*: The numbering is based on the amino acid sequence of "RJP70" and it starts from "Ala" at the N-terminus.

**[0019]** The anti-allergic protein used in the present invention usually consists of the amino acid sequence completely encoded by the nucleotide sequence of SEQ ID NO: 5 or 6. It also can comprise any amino acid sequence partially encoded by the nucleotide sequence of SEQ ID NO: 5 or 6 as long as it comprises the amino acid sequence of either SEQ ID NO: 1 or 2. The amino acid sequence of the protein can be advantageously altered by deletion, replacement, insertion and/or addition of one or more amino acid residues according to usual recombinant DNA technique such as site specific mutagenesis in such a manner that the anti-allergic activity of the protein originally encoded by the DNA is not substantially eliminated. To keep anti-allergic activity, the altering percentage of the amino acid sequence of the protein is preferably limited to less than about 35% of the whole the amino acid sequence in view of about 66% amino acid homology between "RJP70" and "RJP55".

**[0020]** The DNA having a nucleotide sequence of SEQ ID NO: 5 or 6 is useful for producing the protein as an effective ingredient of the anti-allergic agent of the present invention according to recombinant DNA technique: The anti-allergic protein can be obtained by artificially expressing the DNA having the nucleotide sequence of SEQ ID NO: 5 or 6 encoding "RJP70" or "RJP55" and then collecting the resulting protein. To express the above DNA, a method of breeding or culturing an appropriate host cell transformed with the DNA or *in vitro* DNA expression system (*in vitro* translation and *in vitro* transcription) can be selectively used.

**[0021]** The transformant for producing "RJP70" or "RJP55" used in the present invention is usually obtained by transforming an appropriate host with the recombinant DNA inserted with the DNA having the nucleotide sequence of SEQ ID NO: 5 or 6 in an autonomously replicable vector DNA. The autonomously replicable vector can be selected from usual vectors suitable to the employed host. Such usual vectors are plasmid vectors illustrated with pBR322, pUC18, Bluescript II SK (+), pUB110, pTZ4, pC194, pHV14, TRp7, YEp7 and pBS7; phage vectors illustrated with  $\lambda$ gt $\cdot$  $\lambda$ C,  $\lambda$ gt $\cdot$  $\lambda$ B, p11,  $\phi$ 1 and  $\phi$ 105; and baculovirus vectors illustrated with pVL1393. When expressing the DNAs of the present invention, pUC118, pUC119, pUC18, pUC19, pBR322, Bluescript II SK(+),  $\lambda$ gt $\cdot$  $\lambda$ C and  $\lambda$ gt $\cdot$  $\lambda$ B are suitable for *E. coli*, and, pUB 110, pTZ4, pC194, p11,  $\phi$ 1 and  $\phi$ 105 are suitable for *Bacillus subtilis*. In the case of replicating the recombinant DNA in two or more hosts, pHV14, TRp7, YEp7 and pBS7 are useful. Such autonomously replicable vectors usually have appropriate nucleotide sequences such as a promoter, enhancer, replication origin, transcription termination site and selection marker sequence for expression of the DNAs of the present invention in each host or for confirmation of a desired transformant. To insert the DNAs in such vectors, any usual technique in the art can be used; such technique can be illustrated with addition of a linker, addition of a restriction enzyme recognition site by PCR method, and treatment with a restriction enzyme or ligase.

**[0022]** Any host cells in the art can be used for transforming with the DNAs of the present invention; such host cells can be illustrated with microorganisms such as *E. coli*, *Bacillus subtilis*, yeasts and fungus; non-vertebrate cells such as insect; plant cell, and vertebrate cell. Since insect cells are enable to provide a more natural protein, they are more preferably used. Such host cells can be introduced with the DNAs of the present invention by applying suitable methods such as phosphate calcium method, electroporation method, virus infection method, DEAE-dextran method, lipofection method, and microinjection method. A desired transformant is cloned from the resulting transformants by checking the presence of the DNAs or the production of an anti-allergic protein. The materials and techniques for obtaining the recombinant DNAs and transformants described above have been taught by J. Sambrook *et al.* in "*MOLECULAR CLONING A LABORATORY MANUAL*", 2nd edition, published by Cold Spring Harbor Laboratory, (1989).

**[0023]** The transformants thus obtained produce anti-allergic proteins intracellularly or extracellularly when cultured under an appropriate condition suitable for the vectors used. Usual culture media containing carbon sources, nitrogen sources and minerals, optionally supplemented with amino acids or vitamins as a micronutrient can be used. The carbon sources are illustrated with sugar sources such as starch, starch hydrolysate, glucose, fructose, sucrose and trehalose. The nitrogen sources are illustrated with nitrogenous non-organic or organic compound such as ammonia or salts thereof, urea, nitrates, peptones, yeast extracts, defatted soybeans, corn steep liquors and meat extracts. Varying with the host cell or the kind of vectors, a used culture containing anti-allergic protein is obtained by culturing a host cell for about one to six days under the condition kept at 20-60 °C and pH 2-10.

**[0024]** The protein obtained by the above recombinant DNA techniques can be used without purification. However, it is usually purified in an appreciate manner to be suitable for its use. Such purification methods for the protein can be chosen from usual methods described in the case of preparation for natural royal jelly.

**[0025]** Proteins, having as a partial amino acid sequence of either SEQ ID NO: 1 or 2 used in the present invention, exhibit a biological activity for inhibiting the production of antibodies or cytokines. The present inventors achieved to identify of proteins, which are main substances for anti-allergic activity of royal jelly, as "RJP70" and "RJP55" by separately purifying the proteins from royal jelly as tracing the activity of inhibiting the production of cytokines in spleen cells from mouse immunized with Alum adjuvant and stimulated with anti CD3 antibody. Similarly as in the case of natural royal jelly, they can be advantageously used to inhibit the onset of allergy induced by an increased production of the above cytokines and antibodies, and relative and treat the symptoms thereof after the onset, since these proteins have been determined *in vitro* and *in vivo* tests to inhibit the production of various cytokines and antibodies such as IL-2, IL-4, IFN- $\gamma$ , TNF- $\alpha$ , IgE and IgG.

**[0026]** The more the anti-allergic agent of the present invention contains a protein comprising the partial amino acid sequence of SEQ ID NO: 1 or 2 as an anti-allergic ingredient, the more it remarkably exhibits the anti-allergic effect. The agent can contain an anti-allergic substance, which has been highly or partially purified or in an intact natural form. The agent preferably contains the protein as an anti-allergic ingredient in a sufficient amount to decrease the relative production of IL-2 to 80% or less or of IL-4 to 60% or less compared to the case lack of the protein when determined by the inhibition test of cytokine production with 2 mg/ml protein concentration described in the following Experiment.

**[0027]** The anti-allergic agent of the present invention effectively alleviates various symptoms caused by allergic diseases, particularly, atopic diseases. The atopic diseases are kind of hypersensitive diseases appearing congenitally and family in various organs, which is illustrated with dermatitis, hay fever, bronchial asthma, urticaria, allergic rhinitis,

insect allergy and mite allergy, as well as a disease caused by type I allergic reaction with immunoglobulin E (IgE).

**[0028]** The following explains uses of the anti-allergic agent of the present invention. The agent can perform the desired anti-allergic effect in an oral or parental administration. An effective dose of the agent can be decided according to kind, age or sex of the objective mammals including humans. When the protein having a partial amino acid sequence of SEQ ID NO: 1 or 2 is used as an effective ingredient, it is orally taken or administrated in an amount of usually 0.01-100 mg/dose, preferably 0.1-50 mg/dose. While observing its effect, the intake or administration is carried out once a day or several times a day on successive days or one or more interval days. The intake or administration is not specifically restricted. For example, it can be optionally chosen from oral route, tube feeding route, percutaneous route, transmucosal route, intravenous route, etc. When the agent is used as an oral anti-atopic agent formed in a food or beverage, more appropriate royal jelly material can be provided in view of economical use by measuring the activity for inhibiting the production of cytokines in some natural royal jelly materials according to the following Experiment 2.

**[0029]** When the anti-allergic agent of the present invention can be prepared as an external agent which is directly applied to the skin such as cosmetics, it contains the anti-allergic ingredient from royal jelly having the amino acid sequence of SEQ ID NO: 1 or 2 in an amount of 0.001 to 10% by weight, preferably, 0.01 to 1% by weight to the total weight of the external agent. It can be directly applied to the skin once a days or one more interval days while observing the effect. The amount of less than 0.001% by weight may be hard to exhibit the effect. The amount of over 10% by weight may not be preferable in view of economical use because of its lesser effect than expected. Usually, the agent contains the ingredient in the above range.

**[0030]** The allergic agent of the present invention can be advantageously used in the form of a composition illustrated with foods, beverages, cosmetics or pharmaceuticals. Optionally, the composition can be incorporated with other ingredients having an anti-allergic effect illustrated with a product of labiate or *Pfaffia* together with royal jelly or anti-allergic proteins. The resulting composition is usually usable in the field of foods, beverages, cosmetics or pharmaceuticals. Further, optionally, the composition may further contain one or more other ingredients than the ingredients described above, for example, water, alcohols, starch, proteins, amino acids, dietary fibers, carbohydrates, lipids, vitamins, minerals, flavors, colorants, sweeteners, seasonings, spices, antiseptics, emulsifiers, surfactants, excipients, fillers, gums, or preservatives. Varying depending on the necessity for the composition in the field, the suitable ingredients can be selected from the above ingredients. The composition containing such ingredients is not restricted to a specific form. It can be provided in the desirable form such as a powder, granule, tablet, paste, jelly, milky lotion or solution.

**[0031]** The above carbohydrates are illustrated with saccharides such as glucose, fructose, lactose, trehalose, maltose, sucrose, lactosucrose, and starch syrup; cyclic saccharides such as cyclodextrins and cyclic tetrasaccharide; sugar alcohols such as erythritol, mannitol, sorbitol, xylitol, maltitol, and hydrogenated starch syrup; high intensity sweeteners such as aspartame, stevia extract and sucralose; natural polysaccharides such as pullulan and carrageenan; gums such as natural gums and synthesized carboxymethylcellulose. One or more of such ingredients can be advantageously used for forming into a product in a solid form and for stabilizing the agent improving its taste, and retaining its flavor.

**[0032]** The compositions containing the anti-allergic agent of the present invention can be produced in considering with objective animals and intake or administration methods. It can be produced by admixing the anti-allergic agent of the present invention with one or more ingredients acceptable in the field of foods, beverages, cosmetics, pharmaceuticals, quasi-drugs, feeds, baits or pet foods in a proper proportion, and optionally, diluting, concentrating, drying, filtrating or centrifuging, and then forming desirably. The order of adding each ingredient and the timing of such processes are not specifically restricted as long as they do not lose the anti-allergic activity of the agent.

**[0033]** In the case of using the composition containing the anti-allergic agent of the present invention as a food, it is illustrated with frozen desserts such as ice creams, ice candies and sherbets; syrups such as sugar syrups; spreads or pastes such as butter creams, custard creams, flour pastes, peanut pastes and fruit pastes; western confectionaries such as chocolates, jellies, candies, gummy jellies, caramels, chewing gums, custard puddings, cream puffs, and sponge cakes; processing fruits or vegetables such as jams, marmalades, syrups, and pickles; Japanese confectionaries such as "manju" (Japanese-style bun stuffed with "azuki"-bean paste), "uiro" (sweetened Japanese-style rice jelly), "an" ("azuki"-bean paste, sweet bean jelly), soft "azuki"-bean jellies, sponge cakes, and hard candies; seasonings such as soy sauces, powdered soy sauces, "miso" (Japanese-style bean paste), powdered "miso", mayonnaises, dressings, vinegars, "san-bai-zu" (a sauce of sugar, soy sauce and vinegar), table sugars, and coffee sugars. In the case of using it as a beverage, it is illustrated with alcoholic drinks such as synthetic "sake", brews, fruit wines, and Western liquors; soft drinks such as juices, mineral waters, soda waters, lactic acid drinks, lactic acid bacteria beverages, sport drinks, nutritious supplement drinks, green teas, black teas, oolong teas, coffees, and cocoas.

**[0034]** In the case of using the agent as a cosmetic, it is prepared in the form of a lotion, cream, milky lotion, gel, powder, paste, or block. It is illustrated with cosmetics for cleaning such as soaps, cosmetic soaps, cleansing powders, face wash creams, face wash foams, facial rinses, body shampoos, body rinses, hair shampoos, hair rinses, and hair cleansing powders; cosmetics for hair such as set lotions, hair blows, stick pomades, hair creams, pomades, hair

sprays, hair liquids, hair tonics, hair lotions, hair restorers, hair dyes, treatments for scrap, hair cosmetics, gloss-imparting hair oils, hair oils and combing oils; base cosmetics such as cosmetic lotions, vanishing creams, emollient creams, emollient lotions, cosmetic packs in the form of a jelly peel off, jelly wiping, paste washing or powders, cleansing creams, cold creams, hand creams, hand lotions, milky lotions, moisture-imparting liquids, after-shaving lotions, shaving lotions, before-shaving lotions, after-shaving foams, after-shaving creams, before-shaving creams, cosmetic oils, and baby oils; makeup cosmetics such as foundations in the form of a liquid, cream or solid, talcum powders, baby powders, body powders, perfume powders, makeup bases, face powders in the form of a cream, paste, liquid, solid or powder, eye shadows, eye creams, mascaras, eyebrow pencils, eyelash makeup, rouges, and rouge lotions; perfume cosmetics such as perfumes, paste perfumes, powder perfumes, *eau de colognes*, perfume *cognes*, and *eau de toilette*; suntan and suntan preventive cosmetics such as suntan creams, suntan lotions, suntan oils, suntan preventive creams, suntan preventive lotions, and suntan preventive oils; nail cosmetics such as manicures, pedicures, nail colors, nail lacquers, enamel removers, nail creams, and nail dressings; eyeliner cosmetics; rouges and lipsticks such as lipsticks, lip creams, paste rouges, and lip-glosses; oral cosmetics such as tooth pastes and mouse washes; bath cosmetics such as bath salts, bath oils and bath cosmetic materials.

[0035] In the case of using the agent as a pharmaceutical, it is illustrated with extracts, elixirs, capsules, granules, pills, ointments for eye, oral mucosal patches, suspensions, emulsions, plasters, suppositories, powders, ethanol preparations, tablets, syrups, injections, tinctures, eye drops, ear drops, nasal drops, trochees, ointments, aromatic water, nasal nebulas, lemonades, liniments, fluidextracts, lotions, poultices, air sprays, embrocations, bath preparations, adhesive preparations, pastes, and cataplasms. The composition used in the above form can be produced according to usual processing manner suitable for desired product by adding the anti-allergic agent to the composition at an appropriate timing. If the desired product is a composition produced through some heating processes, the agent should not be added to the composition before the last heating process to avoid the decrease of the anti-allergic activity. Concretely, the agent should be added to the composition after cooled down to 30°C, preferably, normal temperature after the last heating process. Such composition usually contains the anti-allergic agent in the amount of 0.01% by weight or more, preferably, 0.1 to 100% by weight.

[0036] The anti-allergic agent of the present invention used as a pharmaceutical for treating or preventing allergic diseases can be applied to metal allergy, delayed contact hypersensitivity, food allergy, drug allergy, and chemical sensitivity, as well as general atopic diseases as described above. Since the agent inhibits the production of IL-2, IL-4, IFN- $\gamma$  and TNF- $\alpha$ , it is useful for alleviating or treating the autoimmune diseases such as multiple sclerosis, polymyositis, rheumatoid arthritis, rheumatoid arthritis, scleroderma, polyarteritis nodosa, active chronic hepatitis, atrophic gastritis, autoimmune hemolytic anemia, azoospermia, Basedow disease, Behçet disease, CRTS syndrome, cold agglutinin hemolytic anemia, ulcerative colitis, Goodpasture syndrome, hyperthyroidism, chronic thyroiditis, idiopathic Addison disease, idiopathic thrombo-cytopenic purpura, juvenile onset type diabetes, leukopenia, myasthenia gravis, paroxysmal cold hemoglobinuria, pernicious anemia, primary biliary cirrhosis, Sjögren syndrome, sympathetic ophthalmitis, systemic lupus erythematosus, and Wegener granulomatosis.

[0037] As described above, the agent exhibits anti-allergic effects. In addition, it can be daily used without affecting living bodies applied therewith. Therefore, since it efficiently enhances the anti-allergic effect in living bodies without causing serious side effects, it attains the prevention, early alleviation or treatment of allergic diseases and maintains healthy condition.

[0038] Recently, royal jelly has been reported to have an anti-allergic effect by Oka H. *et al.* ("Biotherapy", Vol. 14, pp. 145-150, (2000)) and Kataoka M. *et al.* ("Natural Medicines", Vol. 55, pp. 174-180, (2001)). However, such previous reports have not mentioned that a particular substance, selected from royal jelly ingredients such as proteins, saccharides, lipids, and others, is a main substance having anti-allergic activity. Therefore, the present invention firstly found the main substance to a protein having a partial amino acid sequence of SEQ ID NO: 1 or 2, and the royal jelly having a remarkable effect on inhibiting the production of cytokines, which can be confirmed by following Experiment 2, would exhibit a remarkable anti-atopic effect when orally administered as described in the following Experiment 7.

[0039] The following experiments explain the royal jelly or the anti-allergic protein used in the present invention in detail.

#### Experiment 1:

##### Preparation of water-soluble protein fraction from royal jelly

[0040] Twenty-five grams of a refrigerated raw royal jelly from Brazil were thawed at room temperature, suspended in 20 mM Tris-HCl buffer (pH8.0) and dialyzed against five liters of the same buffer to remove low molecular substances from the royal jelly. The resulting dialysate was centrifuged (12,000 rpm, 15 minutes) to remove insoluble substances and filtrated with a 0.22- $\mu$ m pore-sized filter to obtain a water-soluble protein fraction from royal jelly.

Experiment 2:Measurement of inhibition activity for the production of cytokines or cell proliferation using mouse spleen cell

[0041] Spleen cells were collected from BALB/c mouse immunized three times with OVA as an antigen and Alum as an adjuvant, and prepared to give concentration of  $5 \times 10^6$  cell/ml. One hundred microliter aliquots of the resulting cell suspension were placed in a 96 wells microplate conjugated with anti-CD3 antibody (5  $\mu$ g/ml). The raw royal jelly used in Experiment 1 or the water-soluble protein fraction obtained in Experiment 1 was diluted to concentration of 2.0 mg/ml or 4.0 mg/ml, and the dilute was added to each well by 50  $\mu$ l. Further, 50  $\mu$ l of the medium were added to each well to give total volume of 200  $\mu$ l. After culturing for 40 hours, the resulting culture medium was collected and provided for measuring each cytokine, IL-2 or IL-4, by usual enzyme liquid immunosorbent assay (ELISA). As a control, phosphate buffer saline (hereinafter, it is abbreviated as "PBS(-)") was prepared instead of using the water-soluble protein fraction from royal jelly. The relative production of cytokine by the raw royal jelly or the water-soluble protein fraction from royal jelly was evaluated as percent value by comparing the each value of sample with the control value defined as 100%. The results are in Table 2.

Table 2

Sample	Protein Concentration (mg/ml)	Relative Production of Cytokine (%)	
		IL-2	IL-4
Control 1: PBS(-)	-	100	100
Control 2: Raw RJ	2.0	103	73
	4.0	72	34
Water-Soluble Protein Fraction from RJ	2.0	76	54
	4.0	43	16
"RJ": Royal Jelly, "IL-2": Interleukin-2, "IL-4": Interleukin-4			

[0042] As shown in Table 2, the tested raw royal jelly and the water-soluble protein fraction from royal jelly inhibited the production of IL-2 or IL-4 dose-dependently. In the case of the raw royal jelly at the protein concentration of 2.0 mg/ml, the relative productions of IL-2 and IL-4 were 103% and 73%, respectively. In the case of the water-soluble protein fraction from royal jelly at the protein concentration of 2.0 mg/ml, the relative productions of IL-2 and IL-4 were 76% and 54%, respectively. These results revealed that the water-soluble protein fraction, which had been purified from royal jelly by removing non-protein substances such as water-soluble low molecular substances such as saccharide and water-insoluble substances using purification techniques such as dialysis and centrifuging, had higher inhibiting effect on the cytokine production (anti-allergic effect) than the raw royal jelly.

Experiment 3:Purification of the anti-allergic proteins from raw royal jelly and physico-chemical property of the proteinsExperiment 3-1:Purification of the anti-allergic proteins from raw royal jelly

[0043] Anti-allergic proteins were purified from a raw royal jelly as following up the inhibition of the cytokine production in spleen cells from mouse immunized with OVA/Alum according to Experiment 2. In addition, in order to calculate cell proliferation, the fluorescence intensity was measured by fluorometry using "Alamar Blue", a pigment as oxidation-reduction indicator commercialized by TREC DIAGNOSTIC Company in a manner of exciting with a wavelength of 544 nm wavelength and measuring with a wavelength of 590 nm. The water-soluble protein fraction obtained in Experiment 1 was applied to an anion-exchanger column chromatography (gel volume 54 ml) using "DEAE-5PW" gel commercialized by Tosoh Corporation, Tokyo, Japan. Since the proteins adsorbed to the gel had the inhibitory effect of the cytokine production and the cell proliferation they were eluted from the gel with sodium chloride solution in the manner of linear gradient of the concentration from 0 to 0.3 M. As a result, objective active proteins eluted at the concentration of about 0.08 M (represented by bold line 1 in FIG. 2) and at about 0.17 to 0.25 M (represented by bold line 2 in FIG. 2) were separately collected as chasing eluting protein by measuring 280 nm of absorbance. In the present



invention, conveniently, the former protein is called as "Active Protein No.1" and the later protein is called as "Active Protein No.2". Followings are results of separately purifying the proteins.

### Experiment 3-2:

#### Purification of "Active Protein No.1"

[0044] The fraction containing "Active Protein No.1" obtained in Experiment 3-1 was dialyzed against 20 mM Tris-HCl (pH8.0) solution containing 0.01 M sodium chloride. The resulting dialysate was applied to an anion-exchanger column chromatography (gel volume 6 ml) using "Resource Q" gel commercialized by Amersham Bioscience Corporation to be absorbed to the gel. The protein was eluted in active fractions near the sodium chloride concentration of 0.1 M in linear gradient from 0 to 0.5 M. The active fractions were collected and dialyzed against the same buffer containing 0.05 M sodium chloride to equilibrate with the buffer. The resulting dialysate was subjected to an affinity column chromatography using 3.3 ml of "Heparin-5PW" gel commercialized by Tosoh Corporation, Tokyo, Japan. The result is in FIG. 3. The "Active Protein No.1" was allowed to adsorb to the gel and elute with saline in linear gradient of the concentration from 0 to 1M. Obtained each fraction was measured by the same method described in Experiments 2 and 3 to select the active fractions having the inhibitory effect of the cytokine production and the cell proliferation. As a result, two active proteins were obtained; an active protein eluted with about 0.15 M saline (represented by bold line 1 in FIG. 3, hereinafter, it is called as "Active Protein No.1-1") and another with about 0.35 M saline (represented by bold line 2 in FIG. 3, hereinafter, it is called as "Active Protein No.1-2"). Both proteins had the following same N-terminal amino acid sequence. The "Active Protein No.1-2" was selected as a candidate to obtain a further purified active protein because the protein had larger molecular weight and higher specific activity than the "Active Protein No.1-1". The fractions containing the "Active Protein No.1-2" was subjected to gel filtration column chromatography using "Superdex 200" gel commercialized by Amersham Bioscience Corporation with 1.5 folds concentration of PBS (phosphate buffer saline). The purified "Active Protein No.1" having the inhibitory effect on the production of cytokines and the cell proliferation was obtained by collecting the active fraction. Total protein and specific activity of the "Active Protein No.1" at each purification step are in Table 3. In the Table 3, values of the active fraction of "DEAE-5PW" and below are of "Active Protein No.1-2".

Table 3

Step of Purification	Volume (ml)	Total Protein (mg)	Relative Production of IL-4 (%)*
Water Soluble Royal Jelly	475	1057	9
"DEAE-5PW"	325	114	23
"RESOURCE Q"	40	80	<2
"Heparin-5PW"	95	38	24
"Superdex 200"	20	30	6

\* Values of the undiluted solution obtained from the step.

[0045] The obtained purified "Active Protein No.1" specimen was subjected to SDS-PAGE using 10% (w/v) gel under a reducing condition with dithiothreitol (DTT) in order to determine the purity of the purified specimen. As a result, it had been observed a single band on SDS-PAGE and realized a highly purified specimen.

### Experiment 3-3:

#### Physico-chemical property of "Active Protein No.1"

##### (1) Molecular weight

[0046] The purified "Active Protein No.1-2" having the effect of inhibiting the production of cytokines and cell proliferation against mouse spleen cell immunized with OVA/Alum prepared in Experiment 3-2 and the partially purified "Active Protein No.1-1" prepared in Experiment 3-2, were subjected to SDS-PAGE under the reducing condition with DTT according to Experiment 3-2. The molecular weights of the proteins were calculated in comparison with "LMW Electrophoresis Calibration Kit", a molecular marker commercialized by Amersham Bioscience Corporation, simultaneously subjected to the SDS-PAGE with the proteins. As a result, "Active Protein No.1-1" was detected as a protein band at the position of about 70 kDa and "Active Protein No.1-2" was detected as a protein band at the position of

about 55 kDa.

## (2) N-terminal amino acid sequences

[0047] N-terminal amino acid sequences of the both proteins prepared in Experiment 3-2, i.e., the purified "Active Protein No.1-2" and partially purified "Active Protein No.1-1", were analyzed with a usual protein sequencer (Model 473A, commercialized by Applied Biosystems). The both proteins had been determined to have N-terminal amino acid sequence at the position 1 to 10 of SEQ ID NO: 1. The "Active Protein No.1-2" having about 70 kDa of molecular weight had been given the name "RJP70" by the present inventors.

## Experiment 3-4:

### Purification of "Active Protein 2"

[0048] The dialysate obtained by dialyzing the fraction containing "Active Protein No.2" prepared in Experiment 3-1 against 20 mM Tris-HCl buffer (pH 8.0) containing 0.01 M saline was subjected to an anion exchange column chromatography using 6 ml gel volume of "Resource Q" gel commercialized by Amersham Bioscience Corporation. The "Active Protein No.2" was adsorbed to the gel and eluted with saline in step gradient of the concentration from 0.1 to 0.4 M. The resulting active fractions containing "Active Protein No.2" were collected, subjected to gel filtration column chromatography using "Superdex 200" gel (gel volume 320ml, commercialized by Amersham Pharmacia Biotech Corporation) and eluted with 1.5 folds concentration of PBS(-). As a result, two active fractions were obtained. The fractions were supposed to separate due to difference of monomer and polymer in considering with a evidence of SDS-PAGE under reducing condition showing that the proteins of both fractions has the same molecular weight of 55 kDa. The both fractions were collected and obtained the purified "Active Protein No.2" having inhibitory effect of cytokine production and cell proliferation against mouse spleen cell immunized with OVA/Alum. The results of total proteins and specific activities are in Table 4.

Table 4

Step of Purification	Volume (ml)	Total Protein (mg)	Relative production of IL-4 (%)*
"DEAE-5PW"	88	40.7	61.2
"RESOURCE Q"	2.8	36.3	22.8
"Superdex 200"	8.5	23	18.9

\*: Values of the undiluted solution obtained from the step.

[0049] The obtained purified "Active Protein No.2" specimen was subjected to SDS-PAGE using 10% (w/v) gel under reducing condition with DTT in order to determine the purity of the purified specimen. As a result, it had been observed as a single band on SDS-PAGE to be a highly purified specimen.

## Experiment 3-5:

### Physico-chemical property of "Active Protein No.2"

#### (1) Molecular weight

[0050] The purified "Active Protein No.2" prepared in Experiment 3-4 was subjected to SDS-PAGE under reducing condition with DTT according to Experiment 3-3. As a result, "Active Protein No.2" was detected as a protein band at the position of about 55 kDa.

#### (2) N-terminal amino acid sequences

[0051] N-terminal amino acid sequences of the purified "Active Protein No.2" were analyzed with a usual protein sequencer (Model 473A, commercialized by Applied Biosystems). The protein had been determined to have N-terminal amino acid sequence at the position 1 to 25 of SEQ ID NO: 2. The "Active Protein No.2" had been given the name "RJP55" by the present inventors.

Experiment 4:Inhibitory effect of the purified "RJP70" specimen on the production of cytokines

**[0052]** The purified "RJP70" specimen prepared in Experiment 3-2 was serially diluted to give the solution at the concentrations of 11.7, 23.4, 46.9, 93.8, 188 and 375 µg/ml. The resulting solutions were examined about the inhibitory effect on the production of cytokines against mouse spleen. The activity on cell proliferation was also examined according to Experiment 3-1. The results are in Table 5.

Table 5

Sample	Relative Production of Cytokines and Cell Proliferation (%)		
	IL-2	IL-4	Cell Proliferation
Control (PBS(-))	100	100	100
11.7 µg/ml of the Purified "RJP70" Specimen	78	93	96
23.4 µg/ml of the Purified "RJP70" Specimen	84	105	100
46.9 µg/ml of the Purified "RJP70" Specimen	62	57	83
93.8 µg/ml of the Purified "RJP70" Specimen	70	41	68
188 µg/ml of the Purified "RJP70" Specimen	63	33	68
375 µg/ml of the Purified "RJP70" Specimen	42	8	49
IL-2: Interleukin-2, IL-4: Interleukin-4			

**[0053]** As shown in Table 5, the purified "RJP70" specimen was revealed to inhibit the production of IL-2 and IL-4 and cell proliferation dose-dependently.

Experiment 5:Effects and cytotoxicity against T cell or macrophage of the purified "RJP70" specimenExperiment 5-1:Effects and cytotoxicity against T cell of the purified "RJP70" specimen

**[0054]** For the purpose of determining the direct effect and cytotoxicity against T cell of the purified "RJP70" specimen, such activity of the specimen was measured by a test using CD4<sup>+</sup> T cell from mouse spleen cell stimulated with anti CD3 antibody. The spleen cell prepared from BALB/c mouse in Experiment 2 was suspended in RPMI1640 medium supplemented with 10% (v/v) of fetal calf serum (FCS). A cell sample containing CD4<sup>+</sup> T cells was separated from the resulting cell suspension by the steps of; removing adhesive cells by keeping on dishes coated with FCS at 37°C for one hour; removing B cells by keeping on dishes coated with goat anti mouse Ig, and; collecting CD4<sup>+</sup> T cells by binding them to dishes coated with anti mouse CD4 antiserum. As a result, the obtained cell sample was occupied 91 to 93% by CD4<sup>+</sup> T cells.

**[0055]** The inhibitory effect of the purified "RJP70" specimen prepared in Experiment 3-2 on the production of cytokines, i.e., IL-2, IL-4 and IFN-γ, was determined by a test using the CD4<sup>+</sup> T cells and the specimens serially diluted to the concentration of 31.3, 62.5, 125 and 250 µg/ml. The relative value was calculated by comparing the purified "RJP70" specimen with a control treated in the same test except using PBS(-) instead of the purified "RJP70" specimen. The numbers of living cells or dead cells were measured by trypan blue dye exclusion method to calculate viability (%) according to the following numerous formula 1 as an indicator for cytotoxicity. The results are in Table 6.

Numerous Formula 1:

$$\text{Viability (\%)} = \left\{ \frac{\text{the number of living cells}}{(\text{the number of living cells}) + (\text{the number of dead cells})} \right\} \times 100$$

Table 6

Sample	Relative Production of Cytokines (%)			Viability (%) Viability (%)
	IL-2	IL-4	IFN- $\gamma$	
Control (PBS(-))	100	100	100	84.1 $\pm$ 2.4
31.3 $\mu$ g/ml of the Purified "RJP70" Specimen	78	97	96	83.8 $\pm$ 2.5
62.5 $\mu$ g/ml of the Purified "RJP70" Specimen	59	84	91	82.7 $\pm$ 1.9
125 $\mu$ g/ml of the Purified "RJP70" Specimen	24	68	68	84.6 $\pm$ 0.1
250 $\mu$ g/ml of the Purified "RJP70" Specimen	3	13	27	85.0 $\pm$ 1.5

[0056] As shown in Table 6, "RJP70" inhibited the production of IL-2, IL-4 and IFN- $\gamma$  in the test using CD4<sup>+</sup> T cells as well as using mouse spleen cells. "RJP70" was thought to have no cytotoxicity from the evidence of no significantly different viability between "RJP70" specimens and the control.

#### Experiment 5-2:

##### Effect and cytotoxicity against macrophage of the purified "RJP70" Specimen

[0057] To determine the direct effect and cytotoxicity against macrophage of "RJP70", this experiment that macrophage prepared from mouse abdomen was stimulated with lipopolysaccharide (LPS) and IFN- $\gamma$  was carried out. BALB/c mouse was injected with 2 ml of 3% Brewer's thioglycollate medium. Ascites was taken from the mouse after three or four days and diluted with RPMI1640 medium supplemented with 10% (v/v) fetal calf serum to prepare the cell suspension at the concentration of  $1 \times 10^6$  cells/ml. The cell suspension was placed in plastic dishes by 10 ml and incubated at 37°C in 5% CO<sub>2</sub> for two hours. After discarding the medium, the dishes were washed twice with the fresh same medium to remove non-adhesive cells. Adhesive cells remaining the dishes were collected as macrophage preparation used in following experiment by suspending with the above medium using cell scraper. The inhibitory effect on the cytokine production was examined using the purified "RJP70" prepared in Experiment 3-2 and the macrophage preparation. In detail, the purified "RJP70" specimen was serially diluted to 150, 300 or 600  $\mu$ g/ml and examined about the inhibitory effect on the production of TNF- $\alpha$  and IL-6. Relative values of the cytokine production were calculated by comparing with the control sample treated in the same manner using PBS(-) instead of the purified "RJP70" specimen. Viability of macrophage as a cytotoxicity was calculated by applying the numbers of living cell and dead cell counted by trypan blue dye exclusion method to the above numerous formula 1. The results are in Table 7.

Table 7

Sample	Relative Production of Cytokines (%)		Viability (%)
	TNF- $\alpha$	IL-6	
Control (PBS(-))	100	100	100
150 $\mu$ g/ml of the Purified "RJP70" Specimen	85	103	96
300 $\mu$ g/ml of the Purified "RJP70" Specimen	74	98	92
600 $\mu$ g/ml of the Purified "RJP70" Specimen	28	99	100

[0058] As shown in Table 7, "RJP70" was revealed to inhibit the production of TNF- $\alpha$  in the test using macrophage with LPS and IFN- $\gamma$  but not the production of IL-6, and have no cytotoxicity from the evidence of no significantly different viability between "RJP70" specimens and the control.

#### Experiment 6:

##### Effect of royal jelly and the purified "RJP70" specimen on inhibiting the production of antibodies

[0059] It was examined how an administration of royal jelly or "RJP70" influenced to the antibody production in a mouse immunized with OVA/Alum. Five of seven weeks-aged female BALB/c mice (commercialized by Charles River Japan, Inc., Kanagawa, Japan) were divided in one group and intraperitoneally immunized three times with 2  $\mu$ g of

OVA and 3 mg of Alum in one week-interval. Royal jelly was the same one used in Experiment 1 and it was dissolved in PBS(-) and applied to mouse by 50 µg per one shot. "RJP70" was prepared in Experiment 3-2 and it was dissolved in PBS(-) and applied to mouse by 0.5, 5 or 50 µg per one shot. Each sample was intraperitoneally applied to the mouse twice; two days and six hours before each the three times of the immunization with OVA/Alum, and totally applied six times. As a control, PBS(-) was applied in the same manner. The results of test group are summarized in Table 8.

Table 8

Group	Sample	Dose/ Times	Number of Mouse	Method of Immunizing (Induction of IgE)
1	PBS(-) (Control 1)	-	5	OVA/Alum 3 times Intraperitoneal
2	Royal Jelly (Control 2)	50µg/mouse 6 times	5	OVA/Alum 3 times Intraperitoneal
3	"RJP70"	50µg/mouse 6 times	5	OVA/Alum 3 times Intraperitoneal
4	"RJP70"	5µg/mouse 6 times	5	OVA/Alum 3 times Intraperitoneal
5	"RJP70"	0.5µg/mouse 6 times	5	OVA/Alum 3 times Intraperitoneal
OVA: egg albumin (antigen) Alum: aluminium hydrate gel (adjuvant)				

[0060] The serum samples were taken from mice after one week from the third immunization. Levels of various antibodies in each serum sample was measured by enzyme immunoassay (EIA) method. Titer of anti-OVA IgE antibody was calculated by calibrating the values measured by captured EIA method with the standard curve made by standard serum (640 U/ml). Each calculated value was analyzed in a manner of comparing test groups with control group, i.e., statistical t-test or Welch test, whether it was significant. Significantly different values in one group were dismissed by applying Smirnov outlier test. The result of anti-OVA IgE antibody was in FIG. 4 while the result of anti-OVA IgG1 antibody was in FIG. 5.

[0061] As shown in FIG. 4, both of royal jelly and "RJP70" were revealed to have the effect on decreasing the titer of anti-OVA IgE antibody. Royal jelly was demonstrated to significantly decrease the titer of anti-OVA IgE antibody down to 61% of control (PBS(-)). The purified "RJP70" specimen was demonstrated to dose-dependently decrease the titer of anti-OVA IgE, concretely, the decreasing rate of the group administered with 0.5 µg/mouse was 13%, 5 µg/mouse was 39%, and 50 µg/mouse was 67%. As shown in FIG. 5, the groups administered with royal jelly or the purified "RJP70" specimen were observed to significantly decrease the titer of anti-OVA IgG1 antibody down to 46-82% of the control as well as that of anti-OVA IgE antibody.

[0062] It was determined by the above results that royal jelly and "RJP70" used in the present invention had the inhibitory effect on allergy reaction from the evidence that they decreased the production of IgE and IgG1 antibody.

#### Experiment 7:

##### Inhibitory effect on atopic dermatitis

[0063] Inhibitory effect on atopic dermatitis of the raw royal jelly used in Experiment 1 and "RJP70" prepared in Experiment 3-2 was examined using "atopic dermatitis model mouse" which was an Nc/Nga mouse (female, five weeks-aged, commercialized by Charles River Japan, Inc., Kanagawa, Japan) induced into dermatitis similar to atopic dermatitis by applying picryl chloride. In detail, the five weeks-aged Nc/Nga mouse was first sensitized by; applying ethanol/acetone mixture (4:1 by volume) containing 5% (w/v) picryl chloride on its abdomen and breast shaved with hair clippers; after four days, applying olive oil containing 1% (w/v) picryl chloride on its back and earlobes in the anesthetized condition; applying the olive oil every other week five times. While 1.0 mg of the raw royal jelly used in Experiment 1 or 0.3 mg of the purified "RJP70" specimen prepared in Experiment 3-2 was orally applied to 10 of the mice by sonde once a day five times a week for six weeks from three days before the first sensitization. Skin condition such as itch, redness, bleeding, edema, abrasion, tissue deficit, formation of crust and dryness was megascopically judged twice a week from three weeks after the first sensitization.

**[0064]** Since mice of the group applied with raw royal jelly and "RJP70" had significantly better condition than mice of control group, raw royal jelly and "RJP70" inhibited the symptoms of atopic disease. The result shows that royal jelly and anti-allergic protein "RJP70" used in the present invention are a substance having the effect on alleviating atopic allergic symptoms.

#### Experiment 8:

##### Acute toxicity test

**[0065]** An appropriate amount of "RJP70" or "RJP55" was dissolved in physiological saline containing 5% by weight of gum Arabic and sterilized by usual filtration. Ten ddY mice weighing 20-25 g were administered with the resulting solution by intraperitoneal injection or oral intake using a sonde, and observed for seven days. As a result, when the maximum dose was 10 mg/kg body weight, no fatal case was observed in all groups. The results verify that anti-allergic protein "RJP70" and "RJP55" used in the present invention are safe substances enable to regular use.

#### Experiment 9:

##### Cloning DNA (cDNA) encoding "RJP70" and "RJP55"

#### Experiment 9-1:

##### Preparation of total RNA from honeybee

**[0066]** Total RNA preparation was carried out using "TOTALLY RNA KIT", an RNA preparation kit commercialized by Ambion Inc., availing usual guanidiniethiocyanate / acidic phenol : chloroform method according to the attached protocol. Twelve heads of imaginal *Apis mellifera* L. were immersed in "denaturalized solution" and homogenized. With 10 ml of the obtained extraction was admixed equal volume of phenol : chloroform : isoamylalcohol (25 : 24 : 1 by volume). After centrifuging, upper layer was collected, then, mixed with 0.1 volume of 3 M sodium acetate solution (pH 4.5) and following equal volume of acidic phenol : chloroform solution. After centrifuging, upper phase was collected and mixed with isopropanol. The resulting solution was kept at -20°C for one hour and centrifuged. The resulting precipitate was washed with 70% (v/v) ethanol solution, dried and dissolved in 300 µl of 0.1 mM ethylenediaminetetraacetic acid (EDTA) solution. The resulting solution was heated at 70°C for 10 minutes, admixed with 150 µl of 7.5 M lithium chloride and 50 mM EDTA, kept at -20°C for one hour and centrifuged. The resulting precipitate was washed with 70% (v/v) ethanol aqueous solution, dried, and dissolved in diethylpyrocarbonate (DEPC) treated water containing 0.5 mM EDTA. Finally, 186 µg of total RNA preparation was obtained.

#### Experiment 9-2:

##### Cloning of cDNA encoding "RJP70"

**[0067]** Five microliter of 1 µg/µl total RNA prepared in Experiment 9-1 was placed into 0.5-ml volume tube and admixed with 5 µl of 0.2 µg/µl random hexanucleotide primer and 50 µl of DEPC treated water. The tube was set on "DNA Thermal Cycler 480" a thermal cycler commercialized by PerkinElmer Inc., heated at 70°C for five minutes and quickly cooled down at 4°C. Then, 20 µl of 5 fold concentration of RT-PCR reaction mixture, 10 µl of 100 mM dithiothreitol, 5 µl of 25 mM dNTP, and 5 µl of 200 U/µl Moloney murine leukemia virus (M-MLV) reverse transcriptase (commercialized by Invitrogen Corporation) were added to the solution. The resulting reaction mixture was kept at 25 °C for 10 minutes, 40°C for 30 minutes, and 99 °C for 5 minutes to obtain first strand cDNA solution through a reaction of reverse transcription. The resulting cDNA was subjected to usual PCR amplification using the synthetic oligonucleotide primers having the nucleotide sequence of SEQ ID NO: 9 as a sense primer and SEQ ID NO: 10 as an antisense primer which were referred to a nucleotide sequence of "MRJP3" disclosed in GenBank database. In detail, 2 µl of the reverse transcriptase product were admixed with 5 µl of 10 fold concentration "ExTaq" reaction mixture, 1 µl of 2.5 U/µl "ExTaq" polymerase, 4 µl of 2.5 mM dNTP, 1 µl of 100 ng/µl sense primer described above, 1 µl of 100 ng/µl antisense primer described above, and sterilized water up to 50 µl of total volume. The reaction mixture was subjected to PCR reaction (35 cycles, at 94 °C for 30 seconds, at 61 °C for 30 seconds and 72 °C for three minutes). When the resulting PCR product was subjected to 0.9% agarose gel electrophoresis, amplified DNA fragments were detected as about 1,600 bp-DNA band. The DNA fragments were collected from the gel by usual extraction method. An aliquot of the obtained DNA was subjected to ligation reaction using "pCR-Script SK(+)" Cloning Kit" with plasmid vector "pCR-Script Cam SK (+)" according to an attached protocol. An aliquot of the reaction mixture was introduced into "XL10-Gold Kan"

an *E. coli* competent cell commercialized by Stratagene to make a transformed *E. coli* according attached protocol. The transformed *E. coli* was placed on LB agar plate (1% sodium chloride, 1% tryptone, 0.5% yeast extract, 2% agar) containing 30 µg/ml chloramphenicol and incubated at 37°C for 16 hours. *E. coli* was picked up from the appearing colony and incubated in LB liquid medium containing 30 µg/ml chloramphenicol at 37°C for 16 hours by shaking.

5 Recombinant DNA was prepared from the resulting *E. coli* by usual method. The recombinant DNA was subjected to sequence analysis according to usual "dideoxy" method using a DNA sequencer model "373A" commercialized by Applied Biosystems, and had the nucleotide sequence of SEQ ID NO: 5 as "RJP70" cDNA. The amino acid sequence of SEQ ID NO: 3 is a mature type protein without 20 amino acid residues corresponding to secretion signal sequence from the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 5.

#### Experiment 9-3:

##### Cloning cDNA encoding "RJP55"

15 **[0068]** A cDNA encoding "RJP55" was cloned and sequenced by the same manner described in Experiment 9-2 except for using PCR primers having the nucleotide sequence of SEQ ID NO: 11 as a sense primer and SEQ ID NO: 12 as an antisense primer selected from the nucleotide sequence of "MRJP1" disclosed in GenBank database and setting PCR reaction condition 35 cycles at 94°C for 30 seconds, at 46°C for 30 seconds, at 72°C for three minutes. The cloned "RJP55" cDNA had the nucleotide sequence of SEQ ID NO: 6. The amino acid sequence of SEQ ID NO: 4 is a mature type protein without one amino acid residue of methionine encoded by start codon "ATG" corresponding to secretion signal sequence from the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 6.

#### Experiment 10:

##### Production of anti-allergic protein by recombinant DNA Technique

##### Experiment 10-1:

##### Preparation of a baculovirus transformed with "RJP70" cDNA

30 **[0069]** Baculovirus for expressing the recombinant protein in insect cell was prepared using "BD BaculoGold Transfection Kit" commercialized by BD Pharmingen Corporation. The recombinant DNA prepared in Experiment 9-2 was digested with restriction enzyme Not I and BamH I. The resultant was subjected to 0.9% (w/v) agarose electrophoresis and the DNA fragment at about 1,600 bp was extracted from the gel and purified. The obtained DNA fragment was

35 ligated to baculovirus transfer vector "pVL1393" at BamH I - Not I recognition site down from polyhedrin promoter using "Ligation Kit Version 2" commercialized by Takara Shuzo Corporation, Kyoto, Japan. An aliquot of the ligation reaction was introduced into "Competent Cell JM109" commercialized by Takara Shuzo Corporation, Kyoto, Japan, to make transformed *E. coli* according to attached protocol. The transformed *E. coli* was placed on an LB agar (2%) plate containing 40 µg/ml ampicillin and incubated at 37°C for 16 hours. The transformed *E. coli* was picked up from an appeared colony and incubated in LB liquid medium containing 40 µg/ml ampicillin at 37°C for 16 hours by shaking. The recombinant DNA was prepared from the *E. coli*, and then, the insertion of "RJP70" cDNA was confirmed. The obtained "RJP70" recombinant vector was named as "pVL1393-rip70-4". Recombinant virus was prepared using Sf9 insect cell (ATCC CRL-1711, fall armyworm) according to attached protocol. The Sf9 cell was placed in six-well plate with TC100 medium supplemented with 10% (v/v) FCS (commercialized by Invitrogen Corporation) and kept for 10

45 minutes to attach the plate bottom. After removing the supernatant, 0.5 ml of "Transfection Buffer A Solution" (Grace's medium containing 10% (v/v) FCS) was thrown into each well. While 1.5 µg of the "pVL1393-rip70-4" and 0.25 µg of "BD Baculovirus DNA" were admixed and incubated for five minutes. To the resultant was added 0.5 ml of "Transfection Buffer B" (125 mM calcium chloride, 140 mM sodium chloride, 25 mM HEPES (pH7.1)). Then 0.5 ml of the resulting solution was thrown into the each well and incubated at 27°C for four hours for infection reaction. As a control, "Buffer B" containing wild type baculovirus was added and infected to Sf9 insect cell in the same manner. The resulting virus solution was amplified by adding 50 to 200 µl of the solution to  $1 \times 10^7$  cells of Sf9 cell and incubating it at 27°C for one week. The resulting culture supernatant was prepared as recombinant virus solution for expression of "RJP70" and virus control solution (wild type virus) by centrifuging.

Experiment 10-2:Preparation of "RJP70" recombinant protein

[0070] "High Five", an insect cell line from *Trichoplusia ni* (commercialized by Invitrogen Corporation) was used as a host cell for the protein expression. Virus infection was carried out by adding 200 µl of recombinant virus of "RJP70" solution to 10 ml of  $1 \times 10^8$  Sf9 cell suspension with "Express Five Non-Serum Medium" commercialized by Invitrogen Corporation and incubating for one hour as mixing every 10 minutes. The resulting solution was admixed with 40 ml of the "Express Five Non-Serum Medium" and incubated at 27°C for one week. The resulting culture supernatant was centrifuged by 15,000 rpm for 30 minutes to remove virus and concentrated by centrifuging with "Ultrafree15 UFV2BTK10 <30000" a limit filtration membrane for under 30 kDa commercialized by Millipore Corporation. The resulting solution was subjected to "PD-10" a gel column packing "Sephadex G-25M" (commercialized by Amersham Bioscience Corporation) to obtain a recombinant "RJP70" solution dissolved in 1.5 fold concentration of PBS(-). The obtained solution was a 20 fold concentrated solution of the starting solution and usable for the following assay. A control solution was prepared in the same manner except of using the virus control solution instead of the "RJP70" recombinant virus solution.

Experiment 10-3:Effect of the recombinant "RJP70" on the production of cytokines

[0071] The inhibitory effect on the production of IL-2 and IL-4 of the recombinant "RJP70" was examined according to the method described in Experiment 2. In detail, the recombinant "RJP70" solution prepared in Experiment 10-2 or the control solution was diluted with 0.5 volume sterilized water. The activities of the resultant were measured. Then, the activity of "RJP70" on the production of cytokines was judgement by calculating relative values comparing with that of control as 100%. The results are in Table 8.

Table 8

Sample	Relative Production of Cytokines (%)	
	IL-2	IL-4
Control (Virus Control)	100	100
20 µg/ml of the Recombinant "RJP70" *	101	86
102 µg/ml of the Recombinant "RJP70" *	60	79
307 µg/ml of the Recombinant "RJP70" *	57	66
920 µg/ml of the Recombinant "RJP70" *	43	49

\*: The values mean a total protein concentration in the supernatant of the virus-infected cell culture.

[0072] As shown in Table 8, recombinant "RJP70" solution inhibited the production of IL-2 and IL-4 dose-dependently. The result was revealed that "RJP70" protein had an anti-allergic effect.

[0073] The following Examples concretely explain the present invention in detail. The present invention is not restricted to the Examples.

Example 1:Anti-allergic agent

[0074] The purified "RJP70" specimen prepared in Experiment 3-2 and determined physico-chemically in Experiment 3-2 was freeze-dried *in vacuo*. One point five parts by weight of the resultant were homogenously admixed with 8.5 parts by weight of "TREHA®", a crystalline hydrous  $\alpha, \alpha$ -trehalose commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and powdered by pulverizer. The resulting powder was passed though a 0.42-mm mesh to prepare the anti-allergic agent of the present invention. The anti-allergic agent was confirmed to have the anti-allergic effect on inhibiting the production of cytokines by testing the effect according to Experiment 2. Further, it was reconfirmed by the same test after 10 days.

[0075] The anti-allergic agent was provided to produce a tablet weighing 200 mg by tablet machine. The product is



a conveniently usable anti-allergic agent exhibiting a remarkable and stable anti-allergic effect even after preservation at normal temperature. The product is useful as a health food in daily use because of its mellow sweet taste.

#### Example 2:

##### Anti-allergic agent

[0076] The anti-allergic agent of the present invention was prepared by mixing following ingredients homogeneously in the manner according to Example 1. As "RJP70" and "RJP55" described below, the purified specimens prepared in Experiment 3-2 and 3-4 and physico-chemically determined in Experiment 3-3 and 3-5 were added after freeze-dried *in vacuo* and weighed. The prepared agent was confirmed to have the stable anti-allergic effect even after preservation at normal temperature according to Experiment 2.

"TREHA®" (an $\alpha,\alpha$ -trehalose commercialized by Hayashibara Shoji Inc., Okayama, Japan)	7.7 parts by weight
Freeze-dried powder of the purified "RJP70" specimen	1.0 part by weight
Freeze-dried powder of the purified "RJP55" specimen	0.4 parts by weight
" $\alpha$ G HESPERIDIN PS" (a saccharide-transferred hesperidin commercialized by Hayashibara Shoji Inc., Okayama, Japan)	4 parts by weight
"PULLAN PF-20" (a pullulan commercialized by Hayashibara Shoji Inc., Okayama, Japan)	0.5 parts by weight

[0077] The anti-allergic agent was provided to produce a tablet weighing about 300 mg by tablet machine. The product is a conveniently usable anti-allergic agent exhibiting a remarkable and stable anti-allergic effect even after preservation at normal temperature. The product is useful as a health food in daily use because of its mellow sweet taste.

#### Example 3:

##### Anti-allergic agent

[0078] The anti-allergic agent of the present invention was prepared by mixing following ingredients homogeneously in the manner according to Example 1. As a partial purified royal jelly described below, "Active Protein No. 1" purified partially by an anion column chromatography using "DEAE-5PW" gel commercialized by Tosoh Corporation, Tokyo, Japan were added after freeze-dried and weighed. The prepared agent was confirmed to have the stable anti-allergic effect even after preservation at normal temperature according to Experiment 2.

"FINETOSE®" (crystalline anhydrous maltose commercialized by Hayashibara Shoji Inc., Okayama, Japan)	7.5 parts by weight
Freeze-dried powder of the partial purified royal jelly	1.5 parts by weight
Maltitol	0.8 parts by weight
L-tryptophan	0.2 parts by weight

[0079] The product is a conveniently usable anti-allergic agent exhibiting a remarkable and stable anti-allergic effect even after preservation at normal temperature. The product is useful as a health food in daily use because of its mellow sweet taste.

#### Example 4:

##### Health beverage

[0080] A composition containing 500 parts by weight of "FINETOSE®" a crystalline anhydrous maltose commercialized by Hayashibara Shoji Inc., Okayama, Japan, 100 parts by weight of the anti-allergic agent prepared in Example 3, 190 parts by weight of powered egg yolk, 200 parts by weight of skim milk, 4.4 parts by weight of sodium chloride, 1.85 parts by weight of potassium chloride, 4 parts by weight of magnesium sulfate, 0.01 part by weight of thiamin, 0.1 part by weight of sodium ascorbate, 0.6 parts by weight of vitamin E acetate, and 0.04 parts by weight of nicotinamide was prepared. Twenty-five parts by weight of the composition were dispersed and dissolved homogeneously in 150 parts by weight of purified water and placed in brown glass bottle by 150 g and sealed.

[0081] The product exhibits stable anti-allergic effect and is supplemented with nutrient sources, and can be advan-

tageously used as a health beverage to keep health, promote growth, or prevent, alleviate and treat allergic symptoms. The product can also be used a composition in oral use or intubation use for animals such as domestic animals as well as humans.

#### Example 5:

##### Chewing gum

[0082] Three parts by weight of heat-softened gum base, two parts by weight of "Crystalline MABIT" a crystalline anhydrous maltitol commercialized by Hayashibara Shoji Inc., Okayama, Japan, two parts by weight of xylitol, and four parts by weight of the anti-allergic agent prepared in Example 2 were admixed together and further mixed with proper amount of a flavor and colorant. The resultant was admixed with 0.5 parts by weight of "RJP70" prepared in Experiment 3-2 as kneeled by roller in a usual manner, and further kneeled, shaped, and packed to obtain a product.

[0083] Since the product has satisfactory texture, taste and flavor as well as an anti-allergic effect, it can be advantageously used as daily used chewing gum.

#### Example 6:

##### Skin external cream

[0084] Following ingredients were admixed together as heated in a usual manner;

Polyoxyethylene glyceryl monostearate	2.0 parts by weight
Glyceryl monostearate, selfemulsifying	5.0 parts by weight
Eikosanyl beheniate	1.0 part by weight
Petrolatum	1.9 parts by weight
Trioctanic trimethylol prop an	10.0 parts by weight.

[0085] The resulting mixture was admixed with following ingredients except the anti-allergic agent. After cooled down below 30°C, the mixture was admixed with the anti-allergic agent and emulsified by homogenizer to produce skin external cream.

1,3-butyleneglycol	5.0 parts by weight
Sodium lactate (solution)	10.0 parts by weight
Methyl parahydroxybenzoate	0.1 part by weight
Peach leaf extract	1.5 parts by weight
Purified water	62.2 parts by weight
The anti-allergic agent powder prepared in Example 1	1.0 part by weight

[0086] Since the cream has satisfactory moisture retention property and alleviates allergic symptom such as atopic dermatitis, it is useful as a skin external cream.

#### Example 7:

##### Liquid preparation

[0087] The purified "RJP70" specimen purified in Experiment 3-2 and then physico-chemically determined in Experiment 3-3 was dissolved in physiological saline to give concentration of 0.1% by weight. The resulting solution was precisely filtrated to obtain a liquid preparation.

[0088] The product is useful for injection, eye drop, or nose drop to alleviate or treat allergic diseases such as polliosis.

#### Example 8:

##### Troche

[0089] Following ingredients were admixed together and treated according to Example 1 to produce the anti-allergic

agent of the present invention in a powder form. The powdery agent was confirmed to have stable anti-allergic effect from a result that it inhibited the cytokine production even after preservation by the test according to Experiment 2.

"FINETOSE®" crystalline anhydrous maltose commercialized by Hayashibara Shoji, Inc., Okayama, Japan

Starch	30 parts by weight
The freeze-dried powder of the purified "RJP70" specimen prepared in Experiment 3-2	30 parts by weight
Crystalline cellulose	10 parts by weight
Hydroxypropyl methyl cellulose	19 parts by weight
Magnesium stearate	10 parts by weight
	1 part by weight

[0090] A troche weighing about 1.0 g sized with 16 mm in diameter and 4 mm in thickness was produced from the anti-allergic agent by tablet machine. The product is a convenient and effective troche exhibiting anti-allergic effect even after preservation at a normal temperature. Since the product has mellow sweetness, it can be advantageously used as daily used troche for oral use to prevent atopic allergy, alleviate the symptom or promote treatment.

#### Example 9:

#### Tablet

[0091] Nine parts by weight of "FINETOSE®" a crystalline anhydrous maltose commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and one part by weight of raw royal jelly (from Brazil) confirmed to have a high level of the inhibition of the cytokine production according to Experiment 2 were admixed together homogeneously. The mixture was kept at 25°C for one night and powdered by pulverizer. The powder was passed through a 0.42-mm mesh in diameter and collect to obtain the powdery anti-allergic agent of the present invention.

[0092] The powdery agent was formed in a tablet weighing about 300 mg by tablet machine. The product is a convenient and effective anti-allergic agent exhibiting even after preservation at normal temperature. Since the product has mellow sweetness, it can be advantageously used as daily used anti-atopic agent for oral use to prevent atopic allergy, alleviate the symptom or promote treatment.

#### INDUSTRIAL APPLICABILITY

[0093] As described above, the present invention is to develop an anti-allergic agent comprising a protein having anti-allergic effect, or royal jelly or a purified royal jelly containing the protein based on a new finding that the protein obtainable from royal jelly or purified royal jelly, or royal jelly or purified royal jelly containing the protein exhibits an anti-allergic effect due to remarkably inhibiting the production of antibody or cytokine for mammals including human. Since the anti-allergic agent of the present invention is not need to concern a serious side effect, it is conveniently and comfortably used for preventing, alleviating and treating various symptoms caused by allergic diseases illustrated with atopic diseases and autoimmune disease against mammals including human. It can also be advantageously used in a form of food, beverage, cosmetic, or pharmaceutical.

[0094] Thus, the present invention has a remarkable effect and will give great contribution to the art.

## SEQUENCE LISTING

5 <110> Ken Hayashibara

<120> Anti-allergic agent

10 <130> W0961

<160> 12

15 <210> 1

<211> 10

20 <212> PRT

<213> Apis mellifera

<400> 1

25 Ala Ala Val Asn His Gln Arg Lys Ser Ala

1 5 10

<210> 2

30 <211> 25

<212> PRT

<213> Apis mellifera

35 <400> 2

Asn Ile Leu Arg Gly Glu Ser Leu Asn Lys Ser Leu Pro Ile Leu His

1 5 10 15

40 Glu Trp Lys Phe Phe Asp Tyr Asp Phe

20 25

45 <210> 3

<211> 524

<212> PRT

50 <213> Apis mellifera

<400> 3

Ala Ala Val Asn His Gln Arg Lys Ser Ala Asn Asn Leu Ala His Ser

55 1 5 10 15

EP 1 541 167 A1

5	Met Lys Val Ile Tyr Glu Trp Lys His Ile Asp Phe Asp Phe Gly Ser	20	25	30
10	Asp Glu Arg Arg Asp Ala Ala Ile Lys Ser Gly Glu Phe Asp His Thr	35	40	45
15	Lys Asn Tyr Pro Phe Asp Val Asp Arg Trp Arg Asp Lys Thr Phe Val	50	55	60
20	Thr Ile Glu Arg Asn Asn Gly Val Pro Ser Ser Leu Asn Val Val Thr	65	70	75
25	Asn Lys Lys Gly Lys Gly Gly Pro Leu Leu Arg Pro Tyr Pro Asp Trp	85	90	95
30	Ser Phe Ala Lys Tyr Glu Asp Cys Ser Gly Ile Val Ser Ala Phe Lys	100	105	110
35	Ile Ala Val Asp Lys Phe Asp Arg Leu Trp Val Leu Asp Ser Gly Leu	115	120	125
40	Val Asn Asn Asn Gln Pro Met Cys Ser Pro Lys Leu Leu Thr Phe Asp	130	135	140
45	Leu Lys Thr Ser Lys Leu Val Lys Gln Val Glu Ile Pro His Asn Ile	145	150	155
50	Ala Val Asn Ala Thr Thr Gly Met Gly Glu Leu Val Ser Leu Ala Val	165	170	175
55	Gln Ala Ile Asp Arg Thr Asn Thr Met Val Tyr Ile Ala Asp Glu Lys	180	185	190
	Gly Glu Gly Leu Ile Met Tyr Gln Asn Ser Asp Asp Ser Phe His Arg	195	200	205

EP 1 541 167 A1

5	Leu Thr Ser Asn Thr Phe Asp Tyr Asp Pro Arg Tyr Thr Lys Leu Thr	210	215	220
10	Val Ala Gly Glu Ser Phe Thr Val Lys Asn Gly Ile Cys Gly Ile Ala	225	230	235 240
15	Leu Ser Pro Val Thr Asn Asn Leu Tyr Tyr Ser Pro Leu Ser Ser His	245	250	255
20	Gly Leu Tyr Tyr Val Asp Thr Glu Gln Phe Arg Asn Pro Gln Tyr Glu	260	265	270
25	Glu Asn Asn Val Gln Tyr Glu Gly Ser Gln Asp Ile Leu Asn Thr Gln	275	280	285
30	Ser Phe Gly Lys Val Val Ser Lys Asn Gly Val Leu Phe Leu Gly Leu	290	295	300
35	Val Gly Asn Ser Gly Ile Ala Cys Val Asn Glu His Gln Val Leu Gln	305	310	315 320
40	Arg Glu Ser Phe Asp Val Val Ala Gln Asn Glu Glu Thr Leu Gln Met	325	330	335
45	Ile Val Ser Met Lys Ile Met Glu Asn Leu Pro Gln Ser Gly Arg Ile	340	345	350
50	Asn Asp Pro Glu Gly Asn Glu Tyr Met Leu Ala Leu Ser Asn Arg Met	355	360	365
55	Gln Lys Ile Ile Asn Asn Asp Phe Asn Phe Asn Asp Val Asn Phe Arg	370	375	380
	Ile Leu Gly Ala Asn Val Asp Asp Leu Met Arg Asn Thr Arg Cys Gly	385	390	395 400

EP 1 541 167 A1

5 Arg Tyr His Asn Gln Asn Ala Gly Asn Gln Asn Ala Asp Asn Gln Asn  
405 410 415

10 Ala Asp Asn Gln Asn Ala Asn Asn Gln Asn Ala Asp Asn Gln Asn Ala  
420 425 430

15 Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Arg Gln Asn Asp Asn  
435 440 445

20 Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg  
450 455 460

25 Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn Gly Asn Lys Gln  
465 470 475 480

30 Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Lys Arg Asn  
485 490 495

35 Gly Asn Arg Gln Asn Asp Asn Gln Asn Asn Gln Asn Asp Asn Asn Arg  
500 505 510

40 Asn Asp Asn Gln Val His His Ser Ser Lys Leu His  
515 520

45 <210> 4  
<211> 413  
<212> PRT  
<213> Apis mellifera  
<400> 4

50 Asn Ile Leu Arg Gly Glu Ser Leu Asn Lys Ser Leu Pro Ile Leu His  
1 5 10 15

55 Glu Trp Lys Phe Phe Asp Tyr Asp Phe Gly Ser Asp Glu Arg Arg Gln  
20 25 30

EP 1 541 167 A1

Asp Ala Ile Leu Ser Gly Glu Tyr Asp Tyr Lys Asn Asn Tyr Pro Ser  
35 40 45

Asp Ile Asp Gln Trp His Asp Lys Ile Phe Val Thr Met Leu Arg Tyr  
50 55 60

Asn Gly Val Pro Ser Ser Leu Asn Val Ile Ser Lys Lys Val Gly Asp  
65 70 75 80

Gly Gly Pro Leu Leu Gln Pro Tyr Pro Asp Trp Ser Phe Ala Lys Tyr  
85 90 95

Asp Asp Cys Ser Gly Ile Val Ser Ala Ser Lys Leu Ala Ile Asp Lys  
100 105 110

Cys Asp Arg Leu Trp Val Leu Asp Ser Gly Leu Val Asn Asn Thr Gln  
115 120 125

Pro Met Cys Ser Pro Lys Leu Leu Thr Phe Asp Leu Thr Thr Ser Gln  
130 135 140

Leu Leu Lys Gln Val Glu Ile Pro His Asp Val Ala Val Asn Ala Thr  
145 150 155 160

Thr Gly Lys Gly Arg Leu Ser Ser Leu Ala Val Gln Ser Leu Asp Cys  
165 170 175

Asn Thr Asn Ser Asp Thr Met Val Tyr Ile Ala Asp Glu Lys Gly Glu  
180 185 190

Gly Leu Ile Val Tyr His Asn Ser Asp Asp Ser Phe His Arg Leu Thr  
195 200 205

Ser Asn Thr Phe Asp Tyr Asp Pro Lys Phe Thr Lys Met Thr Ile Asp  
210 215 220



EP 1 541 167 A1

Gly Glu Ser Tyr Thr Ala Gln Asp Gly Ile Ser Gly Met Ala Leu Ser  
225 230 235 240

Pro Met Thr Asn Asn Leu Tyr Tyr Ser Pro Val Ala Ser Thr Ser Leu  
245 250 255

Tyr Tyr Val Asn Thr Glu Gln Phe Arg Thr Ser Asp Tyr Gln Gln Asn  
260 265 270

Asp Ile His Tyr Glu Gly Val Gln Asn Ile Leu Asp Thr Gln Ser Ser  
275 280 285

Ala Lys Val Val Ser Lys Ser Gly Val Leu Phe Phe Gly Leu Val Gly  
290 295 300

Asp Ser Ala Leu Gly Cys Trp Asn Glu His Arg Thr Leu Glu Arg His  
305 310 315 320

Asn Ile Arg Thr Val Ala Gln Ser Asp Glu Thr Leu Gln Met Ile Ala  
325 330 335

Ser Met Lys Ile Lys Glu Ala Xaa Pro His Val Pro Ile Phe Asp Arg  
340 345 350

Tyr Ile Asn Arg Glu Tyr Ile Leu Val Leu Ser Asn Lys Met Gln Lys  
355 360 365

Met Val Asn Asn Asp Phe Asn Phe Asp Asp Val Asn Phe Arg Ile Met  
370 375 380

Asn Ala Asn Val Asn Glu Leu Ile Leu Asn Thr Arg Cys Glu Asn Pro  
385 390 395 400

Asp Asn Asp Arg Thr Pro Phe Lys Ile Ser Ile His Leu  
405 410

&lt;210&gt; 5

&lt;211&gt; 1635

&lt;212&gt; DNA

&lt;213&gt; Apis mellifera

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1635)

&lt;220&gt;

&lt;221&gt; mat\_peptide

&lt;222&gt; (61)..(1632)

&lt;400&gt; 5

atg aca aag tgg ttg ttg ctg gtg gtg tgc ctt ggt ata gct tgt caa 48

Met Thr Lys Trp Leu Leu Leu Val Val Cys Leu Gly Ile Ala Cys Gln

-20

-15

-10

-5

gat gta aca agc gca gct gtg aat cat caa aga aaa tct gca aat aat 96

Asp Val Thr Ser Ala Ala Val Asn His Gln Arg Lys Ser Ala Asn Asn

1

5

10

ttg gca cat tct atg aaa gtg atc tac gaa tgg aaa cac att gat ttt 144

Leu Ala His Ser Met Lys Val Ile Tyr Glu Trp Lys His Ile Asp Phe

15

20

25

gat ttc ggt agc gat gaa aga aga gat gct gcg att aaa tct ggc gaa 192

Asp Phe Gly Ser Asp Glu Arg Arg Asp Ala Ala Ile Lys Ser Gly Glu

30

35

40

ttt gat cac aca aaa aat tat cct ttc gat gtg gac aga tgg cgt gat 240

Phe Asp His Thr Lys Asn Tyr Pro Phe Asp Val Asp Arg Trp Arg Asp

45

50

55

60

aag aca ttt gtc acc ata gaa agg aac aat ggt gta cct tct tct ttg 288

Lys Thr Phe Val Thr Ile Glu Arg Asn Asn Gly Val Pro Ser Ser Leu

65

70

75

aac gig gta act aat aaa aag ggc aaa ggt gga cct ctt cta cga cca 336

**EP 1 541 167 A1**

```

Asn Val Val Thr Asn Lys Lys Gly Lys Gly Gly Pro Leu Leu Arg Pro
      80                               85                             90
5                                     .
tat cct gat tgg tcg ttt gcc aaa tac gaa gat tgc tct gga att gtg 384
Tyr Pro Asp Trp Ser Phe Ala Lys Tyr Glu Asp Cys Ser Gly Ile Val
10                                95                        100                105

agc gct ttc aaa att gcg gtc gac aaa ttt gac aga tta tgg gtt ctg 432
Ser Ala Phe Lys Ile Ala Val Asp Lys Phe Asp Arg Leu Trp Val Leu
15                            110                     115                 120

gac tca ggt ott gtc aat aat aat caa cct atg tgc tct cca aaa ttg 480
Asp Ser Gly Leu Val Asn Asn Asn Gln Pro Met Cys Ser Pro Lys Leu
20                           125                      130                  135                    140

tta acc ttt gat ctg aaa acc tca aaa ttg gtt aag caa gtc gag ata 528
Leu Thr Phe Asp Leu Lys Thr Ser Lys Leu Val Lys Gln Val Glu Ile
25                              145                          150              155

cca cat aat att gcc gta aac gcc acc aca gga atg gga gaa tta gtt 576
Pro His Asn Ile Ala Val Asn Ala Thr Thr Gly Met Gly Glu Leu Val
30                                  160                         165                   170

tca cta gct gtt caa gct ata gat cgf acg aat act atg gtg tac ata 624
Ser Leu Ala Val Gln Ala Ile Asp Arg Thr Asn Thr Met Val Tyr Ile
35                                      175                       180               185

gca gac gaa aaa ggc gaa ggt tta atc atg tat caa aac tcc gac gat 672
Ala Asp Glu Lys Gly Glu Gly Leu Ile Met Tyr Gln Asn Ser Asp Asp
40                                          190                      195                200

tcc ttc cat cga ttg act tcc aat act ttc gat tac gat ccc aga tat 720
Ser Phe His Arg Leu Thr Ser Asn Thr Phe Asp Tyr Asp Pro Arg Tyr
45                                              205                     210                 215                    220

acc aaa ttg aca gtc gct gga gaa agt ttc aca gtg aaa aat gga att 768

```

EP 1 541 167 A1

Thr Lys Leu Thr Val Ala Gly Glu Ser Phe Thr Val Lys Asn Gly Ile  
225 230 235

5

tgt gga att gca ctt agt ccc gtg acg aac aat ctt tat tac agc cct 816  
Cys Gly Ile Ala Leu Ser Pro Val Thr Asn Asn Leu Tyr Tyr Ser Pro  
240 245 250

10

ctc tct tct cac ggt ttg tat tat gtt gat acg gaa caa ttc agg aat 864  
Leu Ser Ser His Gly Leu Tyr Tyr Val Asp Thr Glu Gln Phe Arg Asn  
255 260 265

15

cca caa tat gaa gaa aat aac gtg caa tat gaa gga tct caa gat att 912  
Pro Gln Tyr Glu Glu Asn Asn Val Gln Tyr Glu Gly Ser Gln Asp Ile  
270 275 280

20

ttg aac act caa tca ttc ggt aaa gta gta tgc aaa aat ggc gtc ctt 960  
Leu Asn Thr Gln Ser Phe Gly Lys Val Val Ser Lys Asn Gly Val Leu  
285 290 295 300

25

ttc ttg gga ctc gtg ggt aat tca ggt att gcc tgc gtg aat gaa cat 1008  
Phe Leu Gly Leu Val Gly Asn Ser Gly Ile Ala Cys Val Asn Glu His  
305 310 315

30

caa gta ctt cag aga gaa agt ttt gat gtt gtc gct cag aat gaa gag 1056  
Gln Val Leu Gln Arg Glu Ser Phe Asp Val Val Ala Gln Asn Glu Glu  
320 325 330

40

aca ctt caa atg atc gtt agt atg aaa atc atg gaa aat ctt cca caa 1104  
Thr Leu Gln Met Ile Val Ser Met Lys Ile Met Glu Asn Leu Pro Gln  
335 340 345

45

tcc ggc aga att aat gat cct gaa ggc aat gaa tat atg ttg gct ttg 1152  
Ser Gly Arg Ile Asn Asp Pro Glu Gly Asn Glu Tyr Met Leu Ala Leu  
350 355 360

50

agt aac aga atg caa aaa ata ata aac aat gat ttt aat ttc aac gac 1200

55

EP 1 541 167 A1

Ser Asn Arg Met Gln Lys Ile Ile Asn Asn Asp Phe Asn Phe Asn Asp  
365 370 375 380

gta aat ttc cga att ttg ggt gcg aat gta gat gac tta atg aga aac 1248

Val Asn Phe Arg Ile Leu Gly Ala Asn Val Asp Asp Leu Met Arg Asn

385 390 395

act cgt tgc gga aga tat cac aat cag aat gct ggc aat cag aat gct 1296

Thr Arg Cys Gly Arg Tyr His Asn Gln Asn Ala Gly Asn Gln Asn Ala

400 405 410

gac aat cag aat gct gac aat cag aat gct aac aat cag aat gct gat 1344

Asp Asn Gln Asn Ala Asp Asn Gln Asn Ala Asn Asn Gln Asn Ala Asp

415 420 425

aat cag aat gct aac aaa caa aat ggt aat aga caa aat gat aac aga 1392

Asn Gln Asn Ala Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Arg

430 435 440

cag aat gat aac aag caa aat ggt aac aga cag aat gat aac aag caa 1440

Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Lys Gln

445 450 455 460

aat ggt aac aga cag aat gat aac aag caa aat ggt aac aga caa aat 1488

Asn Gly Asn Arg Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn

465 470 475

ggt aac aaa cag aat gat aac aag caa aat ggt aac aga cag aat gat 1536

Gly Asn Lys Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp

480 485 490

aac aag agg aat ggt aac agg caa aat gat aat caa aat aat cag aat 1584

Asn Lys Arg Asn Gly Asn Arg Gln Asn Asp Asn Gln Asn Asn Gln Asn

495 500 505

gat aat aat cga aat gat aat caa gtt cat cat tct tca aaa tta cat 1632

Asp Asn Asn Arg Asn Asp Asn Gln Val His His Ser Ser Lys Leu His  
 510 515 520

5

taa 1635

10

<210> 6

15

<211> 1245

<212> DNA

<213> Apis mellifera

<220>

20

<221> CDS

<222> (1)..(1245)

<220>

25

<221> mat\_peptide

<222> (4)..(1242)

<400> 6

30

atg aac att ctt cga gga gag tct tta aac aaa tca tta ccc atc ctt 48  
 Met Asn Ile Leu Arg Gly Glu Ser Leu Asn Lys Ser Leu Pro Ile Leu  
 -1 1 5 10 15

35

cac gaa tgg aaa ttc ttt gat tat gat ttc ggt agc gat gaa aga aga 96  
 His Glu Trp Lys Phe Phe Asp Tyr Asp Phe Gly Ser Asp Glu Arg Arg  
 20 25 30

40

caa gat gca att cta tct ggc gaa tac gac tac aag aat aat tat cca 144  
 Gln Asp Ala Ile Leu Ser Gly Glu Tyr Asp Tyr Lys Asn Asn Tyr Pro  
 35 40 45

45

tcc gac att gac caa tgg cat gat aag att ttt gtc acc atg ctg aga 192  
 Ser Asp Ile Asp Gln Trp His Asp Lys Ile Phe Val Thr Met Leu Arg  
 50 55 60

50

tac aat ggc gta cct tcc tct ttg aac gtg ata tct aaa aag gtc ggt 240  
 Tyr Asn Gly Val Pro Ser Ser Leu Asn Val Ile Ser Lys Lys Val Gly

55

EP 1 541 167 A1

65

70

75

5

gat ggt ggt cct ctt cta caa cct tat ccc gat tgg tgc ttt gct aaa 288

Asp Gly Gly Pro Leu Leu Gln Pro Tyr Pro Asp Trp Ser Phe Ala Lys

80

85

90

95

10

tat gac gat tgc tct gga atc gtg agc gcc tca aaa ctt gcg atc gac 336

Tyr Asp Asp Cys Ser Gly Ile Val Ser Ala Ser Lys Leu Ala Ile Asp

100

105

110

15

aaa tgc gac aga ttg tgg gtt ctg gac tca ggt ctt gtc aat aat act 384

Lys Cys Asp Arg Leu Trp Val Leu Asp Ser Gly Leu Val Asn Asn Thr

115

120

125

20

caa ccc atg tgt tct cca aaa ctg ctc acc ttt gat ctg act acc tgc 432

Gln Pro Met Cys Ser Pro Lys Leu Leu Thr Phe Asp Leu Thr Thr Ser

130

135

140

25

caa ttg ctc aag caa gtt gaa ata cca cat gat gtt gcc gta aat gcc 480

Gln Leu Leu Lys Gln Val Glu Ile Pro His Asp Val Ala Val Asn Ala

145

150

155

30

act aca gga aag gga aga tta tca tct cta gct gtt caa tct tta gat 528

Thr Thr Gly Lys Gly Arg Leu Ser Ser Leu Ala Val Gln Ser Leu Asp

160

165

170

175

35

tgc aat aca aat agc gat act atg gtg tac ata gca gac gag aaa ggt 576

Cys Asn Thr Asn Ser Asp Thr Met Val Tyr Ile Ala Asp Glu Lys Gly

180

185

190

40

gaa ggt tta atc gtg tat cat aat tct gat gat tcc ttc cat cga ttg 624

Glu Gly Leu Ile Val Tyr His Asn Ser Asp Asp Ser Phe His Arg Leu

195

200

205

50

act tcc aac act ttc gat tac gat cct aaa ttt acc aaa atg acg atc 672

Thr Ser Asn Thr Phe Asp Tyr Asp Pro Lys Phe Thr Lys Met Thr Ile

55

EP 1 541 167 A1

210

215

220

5

gat gga gaa agt tac aca gcc caa gat gga att tct gga atg gct ctt 720

Asp Gly Glu Ser Tyr Thr Ala Gln Asp Gly Ile Ser Gly Met Ala Leu

225

230

235

10

agt ccc atg act aac aat ctc tat tac agt cct gta gct tcc acc agt 768

Ser Pro Met Thr Asn Asn Leu Tyr Tyr Ser Pro Val Ala Ser Thr Ser

240

245

250

255

15

ttg tat tat gtt aac acg gaa caa ttc aga aca tcc gat tat caa cag 816

Leu Tyr Tyr Val Asn Thr Glu Gln Phe Arg Thr Ser Asp Tyr Gln Gln

260

265

270

20

aat gac ata cat tac gaa gga gtc caa aat att ttg gat acc caa tcg 864

Asn Asp Ile His Tyr Glu Gly Val Gln Asn Ile Leu Asp Thr Gln Ser

275

280

285

25

tcc gct aaa gta gta tca aag agt ggc gtt ctc ttc ttc gga ttg gtg 912

Ser Ala Lys Val Val Ser Lys Ser Gly Val Leu Phe Phe-Gly Leu Val

290

295

300

30

ggc gat tca gct ctt ggc tgc tgg aac gaa cat cga aca ctt gaa aga 960

Gly Asp Ser Ala Leu Gly Cys Trp Asn Glu His Arg Thr Leu Glu Arg

305

310

315

35

cac aat atc cgt acc gtc gct caa agt gat gag act ctt caa atg atc 1008

His Asn Ile Arg Thr Val Ala Gln Ser Asp Glu Thr Leu Gln Met Ile

320

325

330

335

40

gct agc atg aag att aag gaa gct ctt cca cac gtg cct ata ttc gat 1056

Ala Ser Met Lys Ile Lys Glu Ala Leu Pro His Val Pro Ile Phe Asp

340

345

350

45

agg tat ata aac cgt gaa tac ata ttg gtt tta agt aac aaa atg caa 1104

Arg Tyr Ile Asn Arg Glu Tyr Ile Leu Val Leu Ser Asn Lys Met Gln

50



**EP 1 541 167 A1**

5  
aaa atg gtg aat aat gac ttc aac ttc gac gat gtt aac ttc aga att 1152  
Lys Met Val Asn Asn Asp Phe Asn Phe Asp Asp Val Asn Phe Arg Ile  
370 375 380

10  
atg aac gcg aat gta aac gaa ttg ata ttg aac act cgt tgc gaa aat 1200  
Met Asn Ala Asn Val Asn Glu Leu Ile Leu Asn Thr Arg Cys Glu Asn  
15 385 390 395

20  
ccc gat aat gat cga aca cct ttc aaa att tca atc cat ttg taa 1245  
Pro Asp Asn Asp Arg Thr Pro Phe Lys Ile Ser Ile His Leu  
400 405 410

25  
<210> 7  
<211> 1830  
<212> DNA  
<213> Apis mellifera  
30 <220>  
<221> CDS  
<222> (35).. (1669)  
<220>  
35 <221> sig\_peptide  
<222> (35).. (94)  
<220>  
40 <221> mat\_peptide  
<222> (95).. (1666)  
<400> 7

45  
gtcaattgga aaatatctgt attatcctag aaaa atg aca aag tgg ttg ttg ctg 55  
Met Thr Lys Trp Leu Leu Leu  
-20 -15

50  
gtg gtg tgc ctt ggt ata gct tgt caa gat gta aca agc gca gct gtg 103  
Val Val Cys Leu Gly Ile Ala Cys Gln Asp Val Thr Ser Ala Ala Val  
-10 -5 1

55

EP 1 541 167 A1

5      aat cat caa aga aaa tct gca aat aat ttg gca cat tct atg aaa gtg 151  
       Asn His Gln Arg Lys Ser Ala Asn Asn Leu Ala His Ser Met Lys Val  
           5                      10                      15

10     atc tac gaa tgg aaa cac att gat ttt gat ttc ggt agc gat gaa aga 199  
       Ile Tyr Glu Trp Lys His Ile Asp Phe Asp Phe Gly Ser Asp Glu Arg  
           20                      25                      30                      35

15     aga gat gct gcg att aaa tct ggc gaa ttt gat cac aca aaa aat tat 247  
       Arg Asp Ala Ala Ile Lys Ser Gly Glu Phe Asp His Thr Lys Asn Tyr  
                   40                      45                      50

20     cct ttc gat gtg gac aga tgg cgt gat aag aca ttt gtc acc ata gaa 295  
       Pro Phe Asp Val Asp Arg Trp Arg Asp Lys Thr Phe Val Thr Ile Glu  
                   55                      60                      65

25     agg aac aat ggt gta cct tct tct ttg aac gtg gta act aat aaa aag 343  
       Arg Asn Asn Gly Val Pro Ser Ser Leu Asn Val Val Thr Asn Lys Lys  
           30                      70                      75                      80

35     ggc aaa ggt gga cct ctt cta cga cca tat cct gat tgg tgc ttt gcc 391  
       Gly Lys Gly Gly Pro Leu Leu Arg Pro Tyr Pro Asp Trp Ser Phe Ala  
           85                      90                      95

40     aaa tac gaa gat tgc tct gga att gtg agc gct ttc aaa att gcg gtc 439  
       Lys Tyr Glu Asp Cys Ser Gly Ile Val Ser Ala Phe Lys Ile Ala Val  
           100                      105                      110                      115

45     gac aaa ttt gac aga tta tgg gtt ctg gac tca ggt ctt gtc aat aat 487  
       Asp Lys Phe Asp Arg Leu Trp Val Leu Asp Ser Gly Leu Val Asn Asn  
                   120                      125                      130

50     aat caa cct atg tgc tct cca aaa ttg tta acc ttt gat ctg aaa acc 535  
       Asn Gln Pro Met Cys Ser Pro Lys Leu Leu Thr Phe Asp Leu Lys Thr  
                   135                      140                      145

55

tca aaa ttg gtt aag caa gtc gag ata cca cat aat att gcc gta aac 583

Ser Lys Leu Val Lys Gln Val Glu Ile Pro His Asn Ile Ala Val Asn

150

155

160

gcc acc aca gga atg gga gaa tta gtt tca cta gct gtt caa gct ata 631

Ala Thr Thr Gly Met Gly Glu Leu Val Ser Leu Ala Val Gln Ala Ile

165

170

175

gat cgt acg aat act atg gtg tac ata gca gac gaa aaa ggc gaa ggt 679

Asp Arg Thr Asn Thr Met Val Tyr Ile Ala Asp Glu Lys Gly Glu Gly

180

185

190

195

tta atc atg tat caa aac tcc gac gat tcc ttc cat cga ttg act tcc 727

Leu Ile Met Tyr Gln Asn Ser Asp Asp Ser Phe His Arg Leu Thr Ser

200

205

210

aat act ttc gat tac gat ccc aga tat acc aaa ttg aca gtc gct gga 775

Asn Thr Phe Asp Tyr Asp Pro Arg Tyr Thr Lys Leu Thr Val Ala Gly

215

220

225

gaa agt ttc aca gtg aaa aat gga att tat gga att gca ctt agt ccc 823

Glu Ser Phe Thr Val Lys Asn Gly Ile Tyr Gly Ile Ala Leu Ser Pro

230

235

240

gtg acg aac aat ctt tat tac agc cct ctt ctt tct cac ggt ttg tat 871

Val Thr Asn Asn Leu Tyr Tyr Ser Pro Leu Leu Ser His Gly Leu Tyr

245

250

255

tat gtt gat acg gaa caa ttc agc aat cca caa tat gaa gaa aat aac 919

Tyr Val Asp Thr Glu Gln Phe Ser Asn Pro Gln Tyr Glu Glu Asn Asn

260

265

270

275

gtg caa tat gaa gga tct caa gat att ttg aac act caa tca ttc ggt 967

Val Gln Tyr Glu Gly Ser Gln Asp Ile Leu Asn Thr Gln Ser Phe Gly

280

285

290

EP 1 541 167 A1

5      aaa gta gta tgc aaa aat ggc gtc ctt ttc ttg gga ctc gtg ggt aat 1015  
       Lys Val Val Ser Lys Asn Gly Val Leu Phe Leu Gly Leu Val Gly Asn  
                     295                      300                      305

10      tca ggt att gcc tgc gtg aat gaa cat caa gta ctt cag aga gaa agt 1063  
       Ser Gly Ile Ala Cys Val Asn Glu His Gln Val Leu Gln Arg Glu Ser  
                     310                      315                      320

15      ttt gat gtt gtc gct cag aat gaa gag aca ctt caa atg atc gtt agt 1111  
       Phe Asp Val Val Ala Gln Asn Glu Glu Thr Leu Gln Met Ile Val Ser  
                     325                      330                      335

20      atg aaa atc atg gaa aat ctt cca caa tcc ggc aga att aat gat cct 1159  
       Met Lys Ile Met Glu Asn Leu Pro Gln Ser Gly Arg Ile Asn Asp Pro  
       340                      345                      350                      355

25      gaa ggc aat gaa tat atg ttg gct ttg agt aac aga atg caa aaa ata 1207  
       Glu Gly Asn Glu Tyr Met Leu Ala Leu Ser Asn Arg Met Gln Lys Ile  
       30                      360                      365                      370

35      ata aac aat gat ttt aat ttc aac gac gta aat ttc cga att ttg ggt 1255  
       Ile Asn Asn Asp Phe Asn Phe Asn Asp Val Asn Phe Arg Ile Leu Gly  
                     375                      380                      385

40      gcg aat gta gat gac tta atg aga aac act cgt tgc gga aga tat cac 1303  
       Ala Asn Val Asp Asp Leu Met Arg Asn Thr Arg Cys Gly Arg Tyr His  
                     390                      395                      400

45      aat cag aat gct ggc aat cag aat gct gac aat cag aat gct gac aat 1351  
       Asn Gln Asn Ala Gly Asn Gln Asn Ala Asp Asn Gln Asn Ala Asp Asn  
                     405                      410                      415

50      cag aat gct aac aat cag aat gct gat aat cag aat gct aac aaa caa 1399  
       Gln Asn Ala Asn Asn Gln Asn Ala Asp Asn Gln Asn Ala Asn Lys Gln  
       55                      420                      425                      430                      435

aat ggt aat aga caa aat gat aac aga cag aat gat aac aag caa aat 1447

Asn Gly Asn Arg Gln Asn Asp Asn Arg Gln Asn Asp Asn Lys Gln Asn

440

445

450

ggt aac aga cag aat gat aac aag caa aat ggt aac aga cag aat gat 1495

Gly Asn Arg Gln Asn Asp Asn Lys Gln Asn Gly Asn Arg Gln Asn Asp

455

460

465

aac aag caa aat ggt aac aga caa aat ggt aac aaa cag aat gat aac 1543

Asn Lys Gln Asn Gly Asn Arg Gln Asn Gly Asn Lys Gln Asn Asp Asn

470

475

480

aag caa aat ggt aac aga cag aat gat aac aag agg aat ggt aac agg 1591

Lys Gln Asn Gly Asn Arg Gln Asn Asp Asn Lys Arg Asn Gly Asn Arg

485

490

495

caa aat gat aat caa aat aat cag aat gat aat aat cga aat gat aat 1639

Gln Asn Asp Asn Gln Asn Asn Gln Asn Asp Asn Asn Arg Asn Asp Asn

500

505

510

515

caa gtt cat cat tct tca aaa tta cat taa atcaatcaat tatcaattaa aat 1692

Gln Val His His Ser Ser Lys Leu His

520

caattaatta agatgtaaat caaattatit ttttaaatat tttttcgtatg taaacaaaat 1752

tttgtaaaat ctttcattat attataaata aataaaaataa atatcgtttt cgcataaaaa 1812

aaaaaaaaaa aaaaaaaaaa

1830

<210> 8

<211> 1430

<212> DNA

<213> Apis mellifera

<220>

<221> CDS

<222> (46).. (1341)

<220>

<221> sig\_peptide

<222> (46).. (102)

<220>

<221> mat\_peptide

<222> (103).. (1341)

<220>

<221> UNSURE

<222> (1134)

<223> n=a or g or c or t

<400> 8

ttcacgtaca atattccatt gcttcgttac tcgcagctta gaaaa atg aca aga ttg 57

Met Thr Arg Leu

-19

ttt atg ctg gta tgc ctt ggc ata gtt tgt caa ggt acg aca ggc aac 105

Phe Met Leu Val Cys Leu Gly Ile Val Cys Gln Gly Thr Thr Gly Asn

-15

-10

-5

1

att ctt cga gga gag tct tta aac aaa tca tta ccc atc ctt cac gaa 153

Ile Leu Arg Gly Glu Ser Leu Asn Lys Ser Leu Pro Ile Leu His Glu

5

10

15

tgg aaa ttc ttt gat tat gat ttc ggt agc gat gaa aga aga caa gat 201

Trp Lys Phe Phe Asp Tyr Asp Phe Gly Ser Asp Glu Arg Arg Gln Asp

20

25

30

gca att cta tct ggc gaa tac gac tac aag aat aat tat cca tcc gac 249

Ala Ile Leu Ser Gly Glu Tyr Asp Tyr Lys Asn Asn Tyr Pro Ser Asp

35

40

45

att gac caa tgg cat gat aag att ttt gtc acc atg ctg aga tac aat 297

Ile Asp Gln Trp His Asp Lys Ile Phe Val Thr Met Leu Arg Tyr Asn

50

55

60

65

ggc gta cct tcc tct ttg aac gtg ata tct aaa aag gtc ggt gat ggt 345

Gly Val Pro Ser Ser Leu Asn Val Ile Ser Lys Lys Val Gly Asp Gly

70

75

80

5

ggt cct ctt cta caa cct tat ccc gat tgg tgc ttt gct aaa tat gac 393  
 Gly Pro Leu Leu Gln Pro Tyr Pro Asp Trp Ser Phe Ala Lys Tyr Asp

85

90

95

10

gat tgc tct gga atc gtg agc gcc tca aaa ctt gcg atc gac aaa tgc 441  
 Asp Cys Ser Gly Ile Val Ser Ala Ser Lys Leu Ala Ile Asp Lys Cys

15

100

105

110

20

gac aga ttg tgg gtt ctg gac tca ggt ctt gtc aat aat act caa ccc 489  
 Asp Arg Leu Trp Val Leu Asp Ser Gly Leu Val Asn Asn Thr Gln Pro

115

120

125

25

atg tgt tct cca aaa ctg ctc acc ttt gat ctg act acc tgc caa ttg 537  
 Met Cys Ser Pro Lys Leu Leu Thr Phe Asp Leu Thr Thr Ser Gln Leu

130

135

140

145

30

ctc aag caa gtt gaa ata cca cat gat gtt gcc gta aat gcc act aca 585  
 Leu Lys Gln Val Glu Ile Pro His Asp Val Ala Val Asn Ala Thr Thr

150

155

160

35

gga aag gga aga tta tca tct cta gct gtt caa tct tta gat tgc aat 633  
 Gly Lys Gly Arg Leu Ser Ser Leu Ala Val Gln Ser Leu Asp Cys Asn

165

170

175

40

aca aat agc gat act atg gtg tac ata gca gac gag aaa ggt gaa ggt 681  
 Thr Asn Ser Asp Thr Met Val Tyr Ile Ala Asp Glu Lys Gly Glu Gly

180

185

190

45

tta atc gtg tat cat aat tct gat gat tcc ttc cat cga ttg act tcc 729  
 Leu Ile Val Tyr His Asn Ser Asp Asp Ser Phe His Arg Leu Thr Ser

195

200

205

50

aac act ttc gat tac gat cct aaa ttt acc aaa atg acg atc gat gga 777  
 Asn Thr Phe Asp Tyr Asp Pro Lys Phe Thr Lys Met Thr Ile Asp Gly

55

EP 1 541 167 A1

	210	215	220	225
5	gaa agt tac aca gcc caa gat gga att tct gga atg gct ctt agt ccc 825			
	Glu Ser Tyr Thr Ala Gln Asp Gly Ile Ser Gly Met Ala Leu Ser Pro			
10	230	235	240	
	atg act aac aat ctc tat tac agt cct gta gct tcc acc agt ttg tat 873			
	Met Thr Asn Asn Leu Tyr Tyr Ser Pro Val Ala Ser Thr Ser Leu Tyr			
15	245	250	255	
	tat gtt aac acg gaa caa ttc aga aca tcc gat tat caa cag aat gac 921			
20	Tyr Val Asn Thr Glu Gln Phe Arg Thr Ser Asp Tyr Gln Gln Asn Asp			
	260	265	270	
	ata cat tac gaa gga gtc caa aat att ttg gat acc caa tgc tcc gct 969			
25	Ile His Tyr Glu Gly Val Gln Asn Ile Leu Asp Thr Gln Ser Ser Ala			
	275	280	285	
	aaa gta gta tca aag agt ggc gtt ctc ttc ttc gga ttg gtg ggc gat 1017			
30	Lys Val Val Ser Lys Ser Gly Val Leu Phe Phe Gly Leu Val Gly Asp			
	290	295	300	305
35	tca gct ctt ggc tgc tgg aac gaa cat cga aca ctt gaa aga cac aat 1065			
	Ser Ala Leu Gly Cys Trp Asn Glu His Arg Thr Leu Glu Arg His Asn			
40	310	315	320	
	atc cgt acc gtc gct caa agt gat gag act ctt caa atg atc gct agc 1113			
45	Ile Arg Thr Val Ala Gln Ser Asp Glu Thr Leu Gln Met Ile Ala Ser			
	325	330	335	
	atg aag att aag gaa gct ctn cca cac gtg cct ata ttc gat agg tat 1161			
50	Met Lys Ile Lys Glu Ala Leu Pro His Val Pro Ile Phe Asp Arg Tyr			
	340	345	350	
	ata aac cgt gaa tac ata ttg gtt tta agt aac aaa atg caa aaa atg 1209			
55	Ile Asn Arg Glu Tyr Ile Leu Val Leu Ser Asn Lys Met Gln Lys Met			



355

360

365

5

gtg aat aat gac ttc aac ttc gac gat gtt aac ttc aga att atg aac 1257

Val Asn Asn Asp Phe Asn Phe Asp Asp Val Asn Phe Arg Ile Met Asn

370

375

380

385

10

gcg aat gta aac gaa ttg ata ttg aac act cgt tgc gaa aat ccc gat 1305

Ala Asn Val Asn Glu Leu Ile Leu Asn Thr Arg Cys Glu Asn Pro Asp

15

390

395

400

aat gat cga aca cct ttc aaa att tca atc cat ttg taa aatctgagtt tt 1356

Asn Asp Arg Thr Pro Phe Lys Ile Ser Ile His Leu

20

405

410

ttgttatata ttaaataattt ctgaaaattt ctttcatta tgaatgtata aaataaatat 1416

25

tgttttcgca taat 1430

&lt;210&gt; 9

30

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

35

&lt;223&gt; Oligonucleotide as PCR sense primer

&lt;400&gt; 9

cctagaaaaa tgacaaagtg gttg 24

40

&lt;210&gt; 10

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

45

&lt;223&gt; Oligonucleotide as PCR anti-sense primer

&lt;400&gt; 10

50

gattttacaa aattttgttt acatcg 26

55

&lt;210&gt; 11

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide as PCR sense primer

<400> 11

gctacatatg aacattcttc gaggagag 28

<210> 12

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide as PCR anti-sense primer

<400> 12

gctaggatcc ctattacaaa tggattgaaa ttttg 35

#### Claims

1. An anti-allergic agent, which comprises as an effective ingredient a protein comprising an amino acid sequence of SEQ ID NO: 1 or a protein comprising an amino acid sequence of SEQ ID NO: 3 where one or more amino acid residues are replaced, inserted or added in such a manner that the anti-allergic activity of the protein is not substantially eliminated.
2. An anti-allergic agent, which comprises as an effective ingredient a protein comprising an amino acid sequence of SEQ ID NO: 2 or a protein comprising an amino acid sequence of SEQ ID NO: 4 where one or more amino acid residues are replaced, inserted or added in such a manner that the anti-allergic activity of the protein is not substantially eliminated.
3. An anti-allergic agent, which comprises royal jelly or purified royal jelly.
4. The agent of claim 3, wherein said purified royal jelly is a water-soluble protein fraction obtained from a royal jelly.
5. The agent of any one of claims 1 to 4, which is **characterized in that** said agent lowers the relative production of interleukin 2 to 80% or less or of interleukin 4 to 60% or less than the case of without the protein of the agent in the inhibition test of cytokine production using a sample with 2 mg/ml protein concentration, disclosed in the specification.
6. A method for inhibiting allergy, which is **characterized in that** use of a composition comprising a protein having an amino acid sequence of SEQ ID NO: 3 or where one or more amino acid residues are replaced, inserted or added in a manner that the activity is not substantially eliminated.
7. A method for inhibiting allergy, which is **characterized in that** use of a composition comprising a protein having

an amino acid sequence of SEQ ID NO: 4 or the protein where one or more amino acid residues are replaced, inserted or added in a manner that the activity of the protein is not substantially eliminated.

- 5
8. The method of claim 6 or 7, wherein said composition is a royal jelly or a purified royal jelly.
9. The method of claim 8, wherein said purified royal jelly is a water-soluble protein fraction from a royal jelly.
10. The method of any one of claims 6 to 9, which is **characterized by** taking or administering the protein of claim 6 or 7 at a dose of 0.01 to 100 mg/kg body weight.
- 10
11. A food or beverage, which comprises the agent of any one of claims 1 to 4.
12. A cosmetic, which comprises the agent of any one of claims 1 to 4.
- 15
13. A pharmaceutical, which comprises the agent of any one of claims 1 to 4.
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55

FIG.1




FIG. 2




FIG.3




FIG. 4





FIG.5





## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/10795

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl. <sup>7</sup> A61K38/17, A61P37/08, A61K7/00, 7/48, 35/64		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl. <sup>7</sup> A61K38/17, A61P37/08, A61K7/00, 7/48, 35/64		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS/MEDLINE/EMBASE/BIOSIS (STN), JOIS (JST)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Mari KATAOKA et al., "Royal jelly no Ko-Allergy Sayo no Kento", Nat.Med., 20 August, 2001 (20.08.01), Vol.55, No.4, pages 174 to 180, ISSN:1340-3443	1-5, 11-13
X	Hideki OKA et al., "Th Saibo Otosei no Chosetsu o Kaishita, Royal jelly no Allergy Han'no Yokusei Sayo", Biotherapy(Tokyo), 29 February, 2000 (29.02.00), Vol.14, No.2; pages 145 to 150, ISSN:0914-2223	1-5, 11-13
X	OKA H. et al., 'Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses.', Int.Immunopharmacol., 2001 March; 1(3): 521-32., ISSN:1567-5769	1-5, 11-13
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 05 November, 2003 (05.11.03)		Date of mailing of the international search report 25 November, 2003 (25.11.03)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/10795

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 9-100236 A (Pola Chemical Industries Inc.), 15 April, 1997 (15.04.97), Claim 1; Par. Nos. [0011] to [0013] (Family: none)	1-5,11-13
Y	Schmitzova J. et al., 'A family of major royal jelly proteins of the honeybee <i>Apis mellifera</i> L.' Cellular and Molecular Life Sciences, 1998; 54(9): 1020-1030. ISSN:1420-682X	1-5,11-13
Y	Albert S. et al., 'Molecular characterization of MRJP3, highly polymorphic protein of honeybee ( <i>Apis mellifera</i> ) royal jelly.', Insect Biochem.Mol. Biol., 1999 May; 29(5): 427-34., ISSN:0965-1748	1-5,11-13

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/10795

**Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.
- ☒
- Claims Nos.: 6 to 10

because they relate to subject matter not required to be searched by this Authority, namely:

Claims 6 to 10 pertain to methods for treatment of the human body by therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.

- 2.
- ☐
- Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3.
- ☐
- Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)